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ABSTRACT 
L-DOPA, the precursor of dopamine, is administered to restore dopamine deficiency in 
Parkinson´s disease (PD) patients. L-DOPA initially provides a sustained symptomatic relief 
with superior efficacy as compared to other treatments, while long term treatment is 
complicated by the gradual emergence of troublesome motor complications i.e. fluctuations in 
therapeutic effect and L-DOPA-induced dyskinesia. The risk for motor complications is 
associated with disease duration and total L-DOPA load. While the underlying mechanisms 
remain to be fully elucidated, the inability of the remaining dopaminergic neurons to buffer 
exogenously applied L-DOPA and pulsatile stimulation of dopamine receptors resulting from 
the short half-life of the drug seem critical. An improved treatment strategy with similar 
efficacy as L-DOPA and reduced side effects is therefore highly warranted.  
Deuterium-L-DOPA was expected to yield dopamine more resistant to enzymatic 
degradation, as deuterium, heavy hydrogen, forms a stronger bond with carbon. Four isoforms 
of deuterium-L-DOPA, carrying different combinations of α and β carbon substitutions, were 
screened for isotope effects on striatal dopamine metabolism by means of in vivo microdialysis 
in intact rats. The triple substituted isoform, α,β,β-D3-L-DOPA (D3-L-DOPA), dramatically 
increased the duration of dopamine output and reduced noradrenaline output as compared to L-
DOPA. These effects most likely reflect reduced activity of the dopamine metabolizing 
enzymes MAO and DβH towards the deuterium substituted α- and β- carbons, respectively. 
Deuterium substitutions thus increase the half-life of dopamine formed from L-DOPA, which 
may reduce pulsatile stimulation of dopamine receptors as well as the total L-DOPA load in PD 
patients. The improved central kinetics of D3-L-DOPA may thereby significantly reduce the 
risk for L-DOPA induced motor complications. Reduced output of noradrenaline from D3-L-
DOPA may additionally contribute to reduce the side effect profile, as noradrenaline released 
from L-DOPA may be involved in the expression of dyskinesias. 
The neurochemical and behavioral effects of D3-L-DOPA were subsequently evaluated in 
two, well-established animal models of PD, the reserpine and the 6-OHDA-lesion model. D3-
L-DOPA produced an increased dopamine output as compared to L-DOPA in the 6-OHDA-
lesioned striatum; an effect which closely resembled that of L-DOPA in combination the 
MAO-B inhibitor selegiline; used in clinical practice to potentiate the symptomatic effect of L-
DOPA and reduce motor fluctuations. Moreover, selegiline pre-treatment did not potentiate the 
effect of D3-L-DOPA. The enhanced output of dopamine from D3-L-DOPA and selegiline/L-
DOPA may thus be attributed to decreased metabolism of dopamine at MAO-B containing 
sites.  
An acute challenge with D3-L-DOPA was shown to produce an increased motor activation 
as compared to L-DOPA in both models of PD, indicating an increased behavioral potency. In 
addition, the behavioral effect produced by D3-L-DOPA was found to be of similar magnitude 
as the combination of selegiline/L-DOPA. Our data hence provide experimental support for the 
potential clinical advantage of D3-L-DOPA and suggest that monotherapy with D3-L-DOPA 
may provide equal benefit as the combination of selegiline/L-DOPA.The effects of D3-L-
DOPA and L-DOPA were also compared in a chronic treatment design. Significantly, a lower 
dose of D3-L-DOPA, 60% of the equivalent L-DOPA dose, produced similar anti-parkinsonian 
benefit while the expression of dyskinesias was markedly reduced. The equivalent dose of D3-
L-DOPA, as compared to L-DOPA, produced a more pronounced anti-parkinsonian effect and 
similar expression of dyskinesia. Taken together, these findings indicate that deuterium 
substitutions offer the advantage of a wider therapeutic window. 
 In conclusion, the increased half-life of dopamine formed from D3-L-DOPA may serve to 
protect dopamine receptors from pulsatile stimulation and the increased behavioral potency of 
D3-L-DOPA may allow for adequate control of parkinsonian symptoms at an overall lower 
dosage. Altogether, a reduced L-DOPA load and more sustained stimulation of dopamine 
receptors may substantially improve PD treatment by reducing the risk for motor fluctuations 
and dyskinesias. Our preclinical data thus provide support for the utility of deuterium-
substitutions in the L-DOPA molecule as a means to improve the therapeutic effect and reduce 
the side effects of L-DOPA therapy.  
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1 INTRODUCTION 
1.1 PARKINSON´S DISEASE 
Parkinson´s disease (PD) is a chronic and progressive movement disorder caused by 
degeneration of dopaminergic neurons in the central nervous system (CNS) and the 
average age of onset is 60 years. The prevalence is reported to be 1 % in the population 
aged over 60 years (de Lau and Breteler, 2006) and 5 million people all over the world 
are estimated to suffer from PD. In 1817, the English physician James Parkinson 
published the first extensive medical description of the disease, “An Essay on the 
Shaking Palsy” (Parkinson, re-published 2002), in which observations of six affected 
patients were presented. The shaking palsy was characterized by “involuntary 
tremulous motion, with lessened muscular power… with a propensity to bend the trunk 
forwards”; the shaking palsy was thereafter named Parkinson´s disease. PD may 
however well have existed for thousands of years before it was described by James 
Parkinson, in fact there are reports of a Parkinson-like disease that dates back to 1000 
before Christ in the “Ayurveda”, the ancient Indian medical system (Manyam, 1990). 
The cardinal motor symptoms of PD include bradykinesia, rigidity, resting tremor and 
postural instability. The motor symptoms typically affect one side of the body at the 
early stage, to extend bilaterally at later stages. Postural instability is commonly 
observed at a later phase in disease progression (Hoehn and Yahr, 1967). The clinical 
diagnosis of PD is based on the manifestation of at least two cardinal symptoms and a 
positive response to dopamine replacement therapy. Non-motor symptoms such as 
orthostatic hypotension, sleep disorders, depression, cognitive dysfunction and 
disturbed autonomic function are also common (Olanow et al., 2009b). Additionally, 
there is a high co-morbidity between PD and dementia (Aarsland et al., 2005).  
 
1.1.1 Discovery of the primary pathophysiology of PD and dopamine 
replacement therapy  
The scientific basis for the discovery of the primary cause of PD symptoms and its 
treatment was laid by Arvid Carlsson and colleagues in the late 1950´s. At the time, 
dopamine was considered to be a physiologically inactive intermediate in the enzymatic 
conversion of the catecholamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) to 
noradrenaline (Carlsson, 2002). The administration of reserpine, an antipsychotic drug, 
to experimental animals became helpful in characterizing the role of central 
catecholamines. Reserpine was shown to induce a parkinsonian-like state that could be 
reversed by administration of L-DOPA (Carlsson et al., 1957). Following the 
identification of dopamine in the CNS, at equal amounts as those of noradrenaline, 
Carlsson and colleagues also showed a depletion of both dopamine and noradrenaline 
by reserpine. In addition, L-DOPA was shown to dramatically increase central levels of 
dopamine but to only slightly increase the levels of noradrenaline (Carlsson et al., 
1958). Taken together these pivotal findings indicated that the reserpine-induced 
suppression of motor function was related to dopamine as was its reversal by L-DOPA. 
Shortly thereafter, dopamine was found to be specifically localized to the basal ganglia 
system (Bertler and Rosengren, 1959, Sano et al., 1959) which is involved in the 
control of movement (see section 1.2). Dopamine was, as opposed to being an inactive 
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intermediate in the production of noradrenaline, therefore suggested to be involved in 
the control of movement (Carlsson, 1959). Spurred by these observations 
Hornykiewicz and colleagues investigated brains of PD-patients and found significantly 
lower levels of dopamine in the basal ganglia compared to control subjects (Ehringer 
and Hornykiewicz, 1960). Thereby, it could be established that PD symptoms were 
associated with dopamine deficieny in the basal ganglia. The first attempts to 
supplement PD-patients with L-DOPA were initiated soon thereafter and L-DOPA was 
shown to improve motor function (Birkmayer and Hornykiewicz, 1961, Sano, re-
published 2000). The clinical effectiveness of L-DOPA was further confirmed during 
long-term treatment (Cotzias et al., 1967, Barbeau, 1969) and in placebo controlled 
trials (Cotzias et al., 1969, Yahr et al., 1969). L-DOPA revolutionized pharmacological 
treatment of PD and still remains the most effective treatment more than 50 years after 
its introduction. Side effects associated with L-DOPA treatment, as observed in the first 
clinical trials, included nausea, vomiting, postural hypotension and psychiatric 
disturbances. An additional side effect, appreciated to represent the most limiting factor 
for the use of L-DOPA, was the appearance of abnormal involuntary movements 
following its administration. Indeed, L-DOPA-induced dyskinesia (LID) is a yet to be 
overcome challenge in PD-treatment (see section 1.4). 
 
1.1.2 Pathophysiology of PD 
The motor symptoms of PD are the result of a severe degeneration of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) which project to the striatum, the 
input zone of the basal ganglia. The accelerated neurodegeneration is suggested to 
occur for many years before symptoms appear (Marsden, 1990). PD symptoms present 
when 50-60% of SNpc cell bodies are lost and striatal tissue levels of dopamine have 
been reduced by about 80% (Bernheimer et al., 1973, Agid, 1991). This indicates a 
remarkale capacity of the dopaminergic system to compensate up until this point 
(Hornykiewicz and Kish, 1987). In fact, the remaining dopaminergic neurons may 
compensate by increasing their synthesis and release (Zigmond et al., 1990). In addition 
to the loss of dopaminergic neurons in the SNpc, a prominent pathological hallmark of 
PD is the presence of neuronal inclusions, Lewy bodies, which are associated with 
excessive neuronal cell death (Gibb and Lees, 1988). Lewy bodies were shown to 
contain high amounts of α-synuclein protein (Spillantini et al., 1997). The distribution 
of Lewy bodies in PD was extensively studied by Braak and subsequently divided into 
six temporal stages of severity. Since Lewy bodies appear in brain stem nuclei such as 
the olfactory nucleus before it appears in the substantia nigra (Braak et al., 2003), it has 
been suggested that cell loss at other sites precede degeneration in the SNpc. Much 
effort has therefore been devoted to identify “pre-motor” symptoms to predict the onset 
of the disease and deficits  in olfaction, REM-sleep and autonomic function are 
potential candidates (Postuma et al., 2012). Other transmitter systems are also affected 
in PD, albeit to variable extent, i.e. noradrenergic neurons in the locus coeruleus (LC) 
(Hornykiewicz and Kish, 1987, Zarow et al., 2003, McMillan et al., 2011), cholinergic 
neurons in the nucleus basalis of Meynert (Zarow et al., 2003) and serotonerigc neurons 
in the median raphe nucleus (Halliday et al., 1990). The degeneration of other 
transmitter systems could thus contribute to non-motor symptoms of the disease 
(Olanow et al., 2009b). 
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1.1.3 Etiology of PD 
Parkinsonism refers to an acquired condition, with known etiology such as induced by 
head trauma, infection or intake of neuroleptics. The etiology of idiopathic Parkinson´s 
disease, however, remains largely unknown and likely depends on a complex 
interaction between genetic and environmental risk factors. A genetic component of PD 
is implicated by the identification of several monogenic familiar variants of PD, i.e. 
where mutations in a single inherited gene can be said to cause the disease and 
additionally by several other gene polymorphisms/mutations which are associated with 
an increased risk for acquiring the disease (Klein and Westenberger, 2012). The 
familiar variants of PD usually have an early disease onset and account for 
approximately 5 % of PD cases (Klein and Westenberger, 2012). Twin studies, 
however, do not support a genetic component in PD with an onset after 50 years of age 
(Tanner et al., 1999). Environmental risk factors with varying epidemiological support 
include age, exposure to certain herbicides, pesticides and heavy metals, rural living 
and well water drinking. Interestingly, tobacco and caffeine intake have been shown to 
reduce the risk of acquiring PD (Swanson et al., 2009, Wirdefeldt et al., 2011).  
 
1.1.4  Pathogenic mechanisms involved in dopaminergic cell death  
Several lines of evidence support mitochondrial dysfunction and increased oxidative 
stress as pathogenic mechanisms in PD. Mitochondrial dysfunction is tightly coupled to 
oxidative stress and excessive generation of reactive oxygen species (ROS) and free 
radicals, which cause damage to membrane lipids, proteins and DNA, all of which were 
found to be affected in PD (Sherer et al., 2002). Specifically, the first electron transfer 
chain in the mitochondria involving NADH (complex 1) has been  found to be impaired 
in the substantia nigra (SN) of PD patients (Schapira and Jenner, 2011). The cause of 
the mitochondrial deficit and oxidative stress could be related to environmental as well 
as genetic risk factors to which dopaminergic neurons have an increased vulnerability. 
As mentioned above, exposure to environmental toxins such as pesticides is associated 
with an increased risk of developing PD, and several pesticides have been shown to 
inhibit  the mitochondrial complex 1 (Sherer et al., 2002). In addition, the synthetic 
opiate 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) can induce irreversible 
Parkinsonism in humans (Langston et al., 1983). MPTP is metabolized to MPP
+
 by 
monoamine oxidase (MAO) -B (Chiba et al., 1984) located in glial cells and taken up 
into the dopaminergic neurons (Javitch et al., 1985) where it interferes with the 
mitochondrial complex 1 (Nicklas et al., 1985). Genetic risk factors, which are 
associated early onset familiar PD, are mutations in the PINK1, DJ1, and Parkin genes, 
all with a suggested involvement in mitochondrial function (Greenamyre and Hastings, 
2004). 
 
The vulnerability of dopaminergic neurons to the above mentioned pathogenic factors 
has been hypothesized to relate to several aspects of dopamine metabolism, which in 
itself may contribute to oxidative stress. Hydrogen peroxide (H2O2), a ROS, is formed 
both in oxidative metabolism of dopamine by MAO and via non-enzymatic 
autoxidation of dopamine into dopamine-quinone (Stokes et al., 1999). Additionally, in 
the presence of ferrous iron (Fe
2+
), which is increased in the SN of PD patients (Dexter 
et al., 1989), the free hydroxyl radical (
•
OH) may be formed from hydrogen peroxide 
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via the Fenton reaction. MAO metabolism of dopamine generates 3, 4- 
dihydroxyphenylacetaldehyde (DOPAL) which is potentially toxic to dopaminergic 
neurons (Panneton et al., 2010). Under normal circumstances DOPAL is rapidly 
converted to the non-toxic metabolite 3, 4- dihydroxyphenylaceticacid (DOPAC) by 
aldehyde dehydrogenase (ALDH). However, products of oxidative stress and 
deficiencies in the mitochondrial complex-1 could decrease the activity of ALDH 
(Eisenhofer et al., 2004, Jinsmaa et al., 2011) resulting in accumulation of DOPAL in 
PD patients. All of the above mentioned mechanisms would occur in the cytosolic 
fraction of dopamine, since the vesicular fraction is protected from metabolism via the 
activity of the vesicular monoamine transporter (VMAT). VMAT, however, operates 
on ATP generated by the mitochondria and mitochondrial dysfunction could thus 
potentially increase the cytosolic contents of dopamine and generate excessive 
oxidative stress via oxidation of dopamine (Sulzer, 2007). A remaining controversy as 
regards L-DOPA treatment of PD is the suggestion that the drug may accelerate the 
degenerative process via increased formation of ROS from autooxidation and oxidative 
metabolism of dopamine. This hypothesis has derived some support from in vitro 
studies, while in vivo studies do not support a toxic effect of L-DOPA in PD (Olanow 
et al., 2004a, Schapira, 2008, Parkkinen et al., 2011, Zesiewicz, 2012). 
 
Other pathogenic mechanisms which are hypothesized to contribute to dopaminergic 
cell death are excessive protein aggregation and accumulation, as shown by the α-
synuclein protein aggregations in Lewy bodies (Greenamyre and Hastings, 2004), 
overstimulation by glutamate and calcium accumulation (excitotoxicity) as well as 
neuroinflammation. The cause and effect relationship between these pathogenic 
mechanisms is far from clear (Jenner and Olanow, 2006).  
 
1.2 THE BASAL GANGLIA, DOPAMINE AND PARKINSON´S DISEASE 
Our movements are categorized in reflexive, rhythmic and voluntary movements, 
which involve different hierarchical levels of the motor system. Unlike reflexes, only 
involving the lower levels of the motor system, the initiation and control of goal-
directed voluntary movements engages all levels of the motor system starting with 
neurons of cerebral cortex to terminate in the motor neurons of spinal cord which 
regulate muscle contraction and relaxation. The basal ganglia constitute a group of 
interconnected subcortical nuclei which receive input from cortical motor, limbic, 
sensory and associative areas and modulate the final output of the same cortical areas 
via a feedback loop relaying in the thalamus. The basal ganglia nuclei also receive 
input from the thalamus, hippocampus and amygdala and send direct projections to the 
brain stem (DeLong, 2000). The basal ganglia-cortical feedback system is organized in 
segregated but parallel circuits connecting specific regions of the cortex to the basal 
ganglia and back, and are functionally divided depending on the cortical origin of the 
circuit (Alexander et al., 1986).The basal ganglia thereby regulate many types of 
behaviors including planning, initiation and execution of voluntary movements as well 
as non-motor behaviors such as cognition and emotion. Dopamine serves to modulate 
basal ganglia function via its prominent innervation of the basal ganglia input zone, the 
striatum.  
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1.2.1 Functional organization of the striatum 
The striatum consists to 95% of medium spiny neurons (MSNs), which function like a 
relay station for all converging inputs to the basal ganglia system (Smith and Bolam, 
1990). In humans, the striatum is divided into the dorsal striatum (caudate nucleus and 
putamen) and the ventral striatum (nucleus accumbens). Based on the cortical and 
subcortical input to the primate striatum it can be functionally divided into modulating 
sensorimotor (dorsal parts of the caudate and putamen), associative (caudate nucleus 
and ventral parts of the putamen) and limbic (nucleus accumbens and most ventral parts 
of the caudate and putamen) functions (Groenewegen, 2003). In rodents, which is the 
animal species studied in the present thesis work, the dorsal striatum is not separated in 
two nuclei and is termed caudate-putamen. Functionally, the rat striatum is divided into 
motor (lateral caudate-putamen), associative (medial caudate-putamen) and limbic 
(nucleus accumbens) (Joel and Weiner, 2000). The hypokinetic symptoms of PD have 
been attributed to dysfunction of the motor circuits of the basal ganglia arising from the 
loss of dopaminergic input to the dorsal striatum (Hornykiewicz and Kish, 1987), 
therefore the following chapters will focus on the motor circuits of the system.  
 
1.2.2 Basal ganglia connections and function 
A simplified scheme of the connections and function of the motor circuit is presented 
below (Albin et al., 1989, DeLong, 1990). Glutamatergic efferents from the motor, 
premotor and somatosensory cortices converge onto dendrites and spines of striatal 
MSNs (Smith and Bolam, 1990).The MSNs are inhibitory projection neurons utilizing 
the transmitter γ-aminobutyric acid (GABA). Striatal MSNs form two functionally 
different pathways, the direct and the indirect, connecting the rest of the basal ganglia 
nuclei to the output structures, the globus pallidus interna (GPi) and the substantia nigra 
pars reticulata (SNr). The output of the basal ganglia is GABAergic and provides a 
tonic inhibition over thalamic neurons which form the excitatory feedback projection to 
the cortex (Bolam et al., 2000). Due to the involvement of different basal ganglia nuclei 
in the direct and the indirect pathway these two circuits mediate antagonistic effects on 
the inhibitory outflow from GPi and SNr (see Figure 1). Striatal MSNs, with a direct 
GABAegric projection to the output structures, will upon activation disinhibit thalamo-
cortical neurons thereby increasing the excitability of cortical motor neurons. MSNs of 
the indirect pathway project to the globus pallidus externa (GPe), which in turn exerts 
tonic inhibitory control of the subthalamic nucleus (STN). The STN in turn projects to 
the output nuclei via glutamatergic efferents. Activation of the striatal MSNs in the 
indirect pathway will thus disinhibit the STN resulting in increased inhibitory outflow 
to the thalamus and decreased excitability of cortical motor neurons. In this way, 
selective activation of the two pathways will modulate the firing rate of basal ganglia 
output nuclei to facilitate or inhibit movement (Albin et al., 1989, DeLong, 1990, 
Gerfen, 1992). Dopamine selectively activates and inhibits the direct and indirect 
pathway, respectively (see section 1.2.3.4). A more complex view of the basal ganglia 
output structures have emerged indicating that not only firing rate but firing pattern of 
output structures are important for the selection of proper motor programs (Obeso et al., 
2000b).  
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Figure 1. Simplified model of basal ganglia connections. The MSNs of the striatum receive 
glutamatergic input from the cortex. The MSNs of the direct pathway send GABAergic projections to the 
SNpr/GPi and will upon activation disinhibit the thalamus and thereby increase cortical activation. The 
MSNs of the indirect pathway send GABAergic projections to the GPe, and will upon activation 
dishinhibit the STN, as a consequence, the inhibitory output from the SNpr/GPi to the thalamus will 
increase and cortical activation decrease. The motor circuit of the basal ganglia receives dopaminergic 
input from the SNpc, direct patway MSNs express stimulatory D1 receptors and indirect pathway MSNs 
express inhibitory D2 receptors.Abbreviations are given in the text. 
 
1.2.3 Dopamine and the basal ganglia  
1.2.3.1 Dopaminergic pathways of the CNS 
There are four major dopaminergic systems in the brain, the mesolimbic, mesocortical, 
tuberoinfundibular and nigrostriatal which are categorized based on the nuclei of origin 
and projection area (see Figure 2).The dopaminergic pathways were first mapped in the 
rodent brain (Dahlström and Fuxe, 1964).The mesolimbic and mesocortical system 
both originate in the ventral tegmental area (VTA) but their projections differ. The 
mesolimbic system innervates the ventral striatum (nucleus accumbens), the amygdala 
and the hippocampus whereas the mesocortical system preferentially projects to cortical 
regions, e.g. the prefrontal cortex. The mesolimbic system and mesocortical systems 
thereby regulate many types of behaviors such as reward, motivation, emotion and 
cognition and several psychiatric conditions are related to alterations in these systems, 
for example schizophrenia and addiction. The tuberoinfundibular system originates in 
the hypothalamus and projects to the pituitary; it is involved in endocrine control. The 
nigrostriatal system originates in the substantia nigra, specifically in the pars compacta 
(Andén et al., 1964), and projects to the striatum. The SNpc is rich in neuromelanin 
pigment, a product formed from autoxidation of dopamine (Sulzer and Zecca, 2000), 
and was hence given the latin name from black nigra. The striatum receives a 
prominent dopaminergic input from cells located in the SN, VTA and retrorubral area, 
midbrain projections to other basal ganglia nuclei have also been detected (Björklund 
and Dunnett, 2007). In both rats and primates a simplified functional subdivision of 
midbrain dopamine projections can be made based on their striatal targets, SNpc 
neurons mainly target the sensorimotor dorsal striatum (caudate-putamen) and VTA 
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neurons mainly target the limbic ventral striatum (nucleus accumbens) (Joel and 
Weiner, 2000, Björklund and Dunnett, 2007). In PD, dopaminergic cell loss is most 
severe in the SNpc but also the VTA neurons are affected (German et al., 1989) which 
may contribute to non-motor symptoms such as impaired cognition, motivation and 
depression. The present thesis work has been focused on the motor aspects of PD and 
all neurochemical measurements were therefore performed in the caudate-putamen.  
 
 
Figure 2. Dopaminergic 
pathways in the human CNS. 
Am: amygdala; Hip: 
hippocampus; Hyp: 
hypothalamus; NAC: nucleus 
accumbens; P: pituitary; PFC: 
prefrontal cortex; SN: 
substantia nigra; Th: thalamus; 
VTA: ventral tegmental area. 
Modified from (Rang et al., 
2012).  
 
 
 
 
1.2.3.2 Dopamine receptors in the striatum  
There are five different G-protein-coupled dopamine receptors (D1-D5). They are 
functionally divided into two families, the D1-like (D1 and D5) and the D2-like (D2, 
D3 and D4) by their association with different G-proteins with opposing effects on the 
membrane enzyme adenylyl cyclase. D1-receptors are coupled to the Gs/olf protein; the 
subunit Gαs/olf stimulates adenylyl cyclase which increases cAMP formation with 
subsequent activation of protein kinase A (PKA). PKA further regulates protein 
function by phosphorylation and targets voltage gated ion-channels and glutamate 
receptors (see section 1.2.3.4). D2 receptors are coupled to the Gi/0 protein and the 
subunit Gαi/o inhibits adenylyl cyclase which decreases the formation of cAMP. In 
addition, the Gβγ subunit can influence excitability of MSNs through direct effects on 
various ion channels (Neve et al., 2004). Both D1 and D2 receptors are found 
postsynaptically on MSNs but are also expressed at extrasynaptic sites (Sesack et al., 
1995, Yung et al., 1995). D2 receptors are also expressed presynaptically in the 
terminal and function as synthesis- and release-modulating autoreceptors (Andén et al., 
1967, Kehr et al., 1972). The MSNs of the direct pathway express D1 receptors, the 
neuropeptides dynorphin and substance P and the MSNs of the indirect pathway 
express D2 receptors and enkephalin (Gerfen et al., 1990, Surmeier et al., 1996).  
 
1.2.3.3 Nigrostriatal transmission  
Dopaminergic cells fire action potentials in two distinct modes, tonic single spike and 
phasic burst firing (Grace and Bunney, 1984a, 1984b). The release of dopamine occurs 
at the terminal and somatodentritic level (Nissbrandt et al., 1985) and is regulated by 
firing rate and pattern of the neuron; phasic firing elicits large transient increases in 
terminal dopamine levels at certain “hot spots”, while tonic firing results in temporally 
and spatially uniform concentrations of dopamine (Venton et al., 2003). The tonic 
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activity of midbrain dopamine neurons thus contribute to constant dopaminergic 
stimulation of dopamine receptors and to the basal concentrations of the transmitter as 
measured by means of in vivo microdialysis (Grace, 2008). The clearance of dopamine 
from the site of its release is mainly governed by diffusion whereas the high-affinity 
reuptake of dopamine via the dopamine transporter (DAT) regulates the concentration 
of diffused dopamine, i.e. the extracellular levels of the transmitter (Cragg and Rice, 
2004). Temporal changes in dopamine cell firing, i.e. transient increases in burst firing 
is important for reward-driven learning and behavior, however the tonic stimulation of 
dopamine receptors, elicited by single spike firing mode, is important for facilitation of 
motor activity (Schultz, 2007). The firing pattern of dopamine neurons is modulated by 
glutamatergic afferents from the cortex and STN (Nieoullon et al., 1978, Chergui et al., 
1991, Smith and Grace, 1992), by GABAergic afferents from STR, GP and SNr (Grace 
and Bunney, 1985, Tepper and Lee, 2007) and by somatodendritic D2 autoreceptors 
(Lacey et al., 1988). In addition, several other transmitter systems projecting to the 
SNpc including noradrenaline, acetylcholine and serotonin are also involved in this 
modulation (Parent et al., 1981, Grenhoff and Svensson, 1988, Kitai et al., 1999).  
 
1.2.3.4 Dopaminergic modulation of striatal MSNs 
The dopaminergic neurons impinge on MSNs to form symmetric synapses on the necks 
of the same dendritic spines that receive cortical input (Bolam et al., 2000). One single 
SNpc cell has been estimated to influence approximately 75 000 MSNs by forming 
huge axonal arborizations (Andén et al., 1966, Matsuda et al., 2009). The classic mode 
of signal transduction is based on synaptic release of dopamine to target postsynaptic 
receptors in the same synapse. However, striatal dopamine receptor activation also 
occurs via volume transmission (Agnati et al., 1986, Garris and Wightman, 1994) 
where dopamine diffuses away from the site of release to target receptors at distant sites 
(Zoli et al., 1998). This mode of transmission may also explain the large number of 
asynaptic contacts found in the striatum (Descarries et al., 1996).The MSN are 
quiescent unless stimulated (Bolam et al., 2000) and exist in a so called “down state”. 
Glutamate released from the corticostriatal neurons activates postsynaptic AMPA and 
NMDA receptors and depolarizes the neuron. If there is sufficient convergent 
excitatory drive from the cortex, the neuron will switch into an “up state” which is near 
spike threshold and during this “up state” the neuron fires. The modulatory role of the 
D1 and D2 receptor on MSN excitability relates to the fact that D1 receptor activation 
increases spiking and D2 receptor activation decreases spiking of MSNs in the “up 
state”. D1-receptor activation will, through the activation of PKA, modulate potassium 
channels, voltage-gated  L-type calcium channels as well as the glutamate receptors α-
Amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA) and N-methyl-D-
aspartate (NMDA)  to increase excitability (Hernandez-Lopez et al., 1997). D2 receptor 
activation will reduce the likelihood of firing by suppressing inward calcium currents 
trough L-type channels, dendritic voltage-gated channels and NMDA receptors in 
addition to an increase in K
+
 outflow (Hernandez-Lopez et al., 2000, Surmeier et al., 
2007, Gerfen and Surmeier, 2011). Additionally, D2-receptor activation may reduce the 
release of glutamate in the striatum (Bamford et al., 2004), thereby further decreasing 
the excitatory drive to the MSN of the indirect pathway. The direct interaction of D1 
and D2 receptor coupled G-proteins will mediate an increased activity of MSNs in the 
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direct pathway and a reduced activity of MSNs in the indirect pathway, respectively, 
hence dopamine signaling will ultimately increase the excitability of cortical motor 
neurons and facilitate movement. Dopamine also modulates long-term changes in 
corticostriatal synaptic strength, which contributes to the storage of information in 
neuronal circuits and may form a base for acquisition and extinction of motor learning. 
The ability of a synapse to alter its strength depending on the input activity is termed 
plasticity. Plasticity at the corticostriatal synapse is implicated in motor learning and 
reward mechanisms. Plasticity can be studied and induced experimentally and has been 
classified into long-term potentiation (LTP) and long-term depression (LTD). 
Dopamine is required for the induction of both forms of plasticity acting together with 
other transmitters and neuromodulators such as acetylcholine, glutamate, adenosine and 
endocannabinoids (Calabresi et al., 2007, Surmeier et al., 2007, Wickens, 2009).  
 
1.2.3.5 Interneurons and other transmitter systems in the basal ganglia 
The modulatory role of dopamine in striatal MSN responsiveness is a complex 
interplay with other types of neurons and chemical mediators. For example, adenosine 
modulates the effects of dopamine in the direct and indirect pathway via A1 receptors 
and A2A receptors, respectively (Ferre et al., 1997). A2A receptors are expressed in the 
indirect pathway MSNs where they can antagonize the effects of D2 receptor activation 
and thus reduce motor activity (Fuxe et al., 2007). Additionally, both cholinergic and 
GABAergic interneurons which are involved in inhibition and activation of specific 
subsets of MSNs express dopamine receptors (Gerfen and Surmeier, 2011). Other 
neurotransmitter systems which project to the striatum include noradrenaline (Lindvall 
and Björklund, 1974, Mason and Fibiger, 1979, Jones and Yang, 1985) and serotonin 
(Parent et al., 2011). 
 
1.2.4 Basal ganglia dysfunction in PD 
From the above depicted basal ganglia model and based on the modulatory role of 
dopamine in the basal ganglia system we can predict that loss of dopaminergic input to 
the MSNs in the striatum will result in hypoactivity of the direct pathway and 
hyperactivity in the indirect pathway. This will result in an excessive inhibitory output 
from the GPi/SNr to the thalamus and decreased excitation of cortical motor neurons 
(Albin et al., 1989, DeLong, 1990) (see Figure 1). In support of this model, lesions of 
the STN of Gpi improve motor symptoms of PD in primate models and patients (Obeso 
et al., 2000b, Obeso et al., 2008a). Depletion of dopaminergic projections to the 
striatum has been found to reduce the expression of direct pathway-associated mRNA 
(dynorphin, substance P) and to increase the expression of enkephalin mRNA 
associated with the indirect pathway (Gerfen et al., 1990). Treatment with L-DOPA or 
dopamine agonists will thus reduce the excessive inhibitory output of the basal ganglia 
system and thereby improve motor function.  
 
The above depicted model of basal ganglia function has helped to understand how 
profound dopamine deficiency results in motor dysfunction and how dopamine 
supplementation may improve PD symptoms. However, it is simplified and in order to 
fully understand all aspects of dysfunction in PD the extended connections between the 
basal ganglia nuclei and the cortex, thalamus and brain stem as well as a complex feed-
Torun Malmlöf 
 
10 
 
back circuitry within the system have to be taken into consideration (Bolam et al., 
2000, Obeso et al., 2000b, Obeso et al., 2008a, Obeso et al., 2008b).  
 
1.3 PHARMACOLOGICAL TREATMENT OF PARKINSON´S DISEASE  
The treatment of PD is purely symptomatic; none of the available pharmacological 
agents have clearly been shown to halt disease progression. Since the introduction of 
long-term L-DOPA treatment during the 60’s (Cotzias et al., 1967, Barbeau, 1969), 
which to a great extent replaced the previous use of anticholinergic drugs (Goetz, 
2011), L-DOPA remains a cornerstone in the pharmacological treatment of PD 
(Mercuri and Bernardi, 2005). The majority of agents used in PD target dopaminergic 
transmission, therefore some relevant aspects of dopamine synthesis, release and 
metabolism will be covered next. 
 
1.3.1 Dopamine synthesis, release and metabolism 
1.3.1.1 Dopamine synthesis and release  
All catecholamines, dopamine, noradrenaline and adrenaline, are produced from L-
tyrosine, a naturally occurring dietary amino acid. L-Tyrosine is actively absorbed from 
the gasterointestinal tract to the circulation and over the blood brain barrier (BBB) via 
the large neutral amino acid (LNAA) transporter. L-Tyrosine is further transported into 
the dopaminergic neuron and hydroxylated to L-DOPA by tyrosine hydroxylase (TH) 
(see Figure 3). This is the rate-limiting step in catecholamine formation. TH activity is 
negatively regulated by presynaptic D2 receptors and positively regulated by an 
increased firing rate of dopaminergic neurons (Cooper et al., 2003). L-DOPA is further 
decarboxylated to dopamine by aromatic amino acid decarboxylase (AADC). AADC 
decarboxylases all naturally occurring amino acids and is widely distributed. In the 
CNS, the enzyme is found in various cells including noradrenergic, dopaminergic and 
serotonergic (Goldstein et al., 1972, Hökfelt et al., 1973). VMAT2 is localized in the 
vesicular membrane (Pickel et al., 1996) and actively transports cytosolic dopamine 
into vesicles. Inside vesicles, dopamine is protected from intraneuronal metabolism. 
The importance of this mechanism is illustrated by the complete depletion of 
catecholamines which occurs following administration of the VMAT-blocker reserpine. 
When an action potential from the soma reaches the synapse, the vesicular membrane is 
fused with the outer nerve cellmembrane and the contents is released into the 
extracellular space via calcium-dependent exocytosis (Westfall and Westfall, 2006). 
Dopamine may however also be released in a non-exocytotic fashion involving 
NMDA-receptor activation (Grace, 1991) and reversed transport of dopamine via the 
DAT (Leviel, 2011). This type of release is not action potential dependent. Following 
release, dopamine activates postsynaptic dopamine receptors via synaptic or volume 
transmission. The DAT is localized at extrasynaptic sites (Pickel et al., 1996) and is, as 
previously mentioned, important for regulation of extracellular levels of dopamine. 
 
1.3.1.2 Dopamine metabolism  
The cytosolic pool of dopamine is subject to metabolism by the enzyme MAO which is 
located in the outer mitochondrial membrane (Greenawalt and Schnaitman, 1970). The 
product of the MAO reaction towards dopamine is the aldehyde DOPAL which is 
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rapidly converted to the corresponding acid, DOPAC by ALDH. ALDH is found in the 
mitochondrial membrane or in a soluble cytosolic form (Marchitti et al., 2007). 
DOPAC is further metabolized by catechol-O-methyltransferase (COMT) to 
homovanillic acid (HVA) in the extracellular space (Kastner et al., 1994, Karhunen et 
al., 1995). Released dopamine is transported back to the dopaminergic neuron or 
metabolized to 3-metoxytyramine (3-MT) by COMT and subsequently to HVA by 
MAO and ALDH. Extracellular dopamine may also be taken up in postsynaptic 
structures via the organic cation transporter or a Na
+
-dependent transporter (Pelton et 
al., 1981, Semenoff and Kimelberg, 1985, Inazu et al., 1999, Westfall and Westfall, 
2006) to be metabolized inside of these cells.  
 
Figure 3. Schematic 
picture of dopamine 
synthesis, release and 
metabolism. The upper 
left compartment 
represents the periphery. 
L-DOPA, administered 
per orally to PD patients, 
is actively transported 
from the periphery to the 
CNS via the LNAA. L-
DOPA is subject to 
extensive peripheral 
metabolism by AADC 
and COMT (see section 
1.3.2). Abbreviations are 
given in the text. Modified 
from (Cooper et al., 
2003). 
 
 
 
 
 
 
 
1.3.1.3 MAO 
The enzyme MAO deserves special attention in this thesis introduction. Besides an 
important role in dopamine metabolism, it is also involved in the oxidative deamination 
of noradrenaline, 5-hydroxytryptamine (5-HT) as well as the amines tryptamine and 
phenyletylamine (PEA). MAO was discovered to exist in two isoforms based on their 
preferential inhibition by clorgyline (MAO-A) (Johnston, 1968) and selegiline (MAO-
B) (Knoll and Magyar, 1972). The isoforms of MAO differ in both tissue distribution 
and substrate specificity. MAO-A is abundantly expressed in the stomach, lungs and 
liver while MAO-B is preferentially found the liver (Berry et al., 1994a). In the CNS, 
there is a compartmentalization of the different isoforms of MAO to certain celltypes. 
MAO-A is mainly found in catecholaminergic neurons, i.e. in noradrenergic neurons of 
the locus coeruleus and in dopaminergic neurons of the SNpc, whereas MAO-B is 
localized in the 5-HT neurons of the raphe nucleus and in glial cells (Levitt et al., 1982, 
Westlund et al., 1985, Thorpe et al., 1987, Westlund et al., 1988, Saura Marti et al., 
1990, Saura et al., 1992, Westlund et al., 1993, Jahng et al., 1997). MAO-A has higher 
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affinity for 5-HT in vitro while MAO-B has higher affinity for PEA. Dopamine, 
noradrenaline, adrenaline are all considered to be mixed substrates for both isoforms 
(Waldmeier, 1987, Berry et al., 1994a). The in vivo contribution of the specific MAO 
isoforms to dopamine metabolism, however depends on their abundance and 
compartmentalization, i.e. which isoform that is present in the cells with access to 
cytosolic dopamine (Waldmeier, 1987). Numerous in vivo pharmacological studies 
have confirmed a predominant role of MAO-A over MAO-B in striatal dopamine 
metabolism in rats (Kato et al., 1986, Butcher et al., 1990, Colzi et al., 1990, Wachtel 
and Abercrombie, 1994, Brannan et al., 1995, Lamensdorf et al., 1996, Fornai et al., 
2000). This finding is consistent with the localization of MAO-A in dopaminergic 
neurons and with the idea that oxidative metabolism of dopamine mainly occurs within 
the dopaminergic neuron (Eisenhofer et al., 2004). However, in human ex vivo studies 
dopamine mainly behaves as a MAO-B substrate (Glover et al., 1977, Garrick and 
Murphy, 1980, O'Carroll et al., 1983) and MAO-B inhibitors are routinely administered 
to PD patients as a means to reduce metabolism of dopamine. The reason for this 
apparent discrepancy is not completely resolved (Berry et al., 1994a, 1994b) but could 
relate to several circumstances. For example, while the compartmentalization of MAO-
A and MAO-B seems to be preserved between species, humans are found to have 
higher MAO-B to MAO-A ratios in the striatum than rats (Fowler et al., 1987, 
Westlund et al., 1988, Saura et al., 1992). In addition, the degree of postsynaptic 
metabolism is suggested to be higher in humans than in rats (Stenström et al., 1987). 
Taken together, both of these species differences indicate that metabolism of dopamine 
to a larger extent depends on postsynaptic MAO-B in humans (Oreland et al., 1983). In 
addition, in PD patients as well as in animal models of PD, the reduced number of 
MAO-A containing dopaminergic terminals could further push the metabolism towards 
MAO-B. This possibility will be discussed in relation to the findings of Paper III (see 
section 4.2).  
 
1.3.1.4 Dopamine synthesis and release in the PD state 
In PD, reduced levels of dopamine are restored by supplementation with the precursor 
L-DOPA (Lloyd et al., 1975). The paradox in this situation is that the neurons which 
normally convert L-DOPA to dopamine degenerate. The intriguing question, which has 
been debated for many years, is where L-DOPA is decaboxylated and from where 
dopamine is subsequently released in the PD brain. The remaining dopaminergic 
neurons are likely responsible for a significant part of the dopamine release in the 
patient. However, in animal models of PD, where almost all dopaminergic neurons are 
destroyed, L-DOPA still produces a significant increase in extracellular dopamine 
(Abercrombie et al., 1990) indicating that other cell types may be involved in the 
production of dopamine from L-DOPA. Preclinical studies have demonstrated that the 
majority of striatal AADC disappear when dopaminergic neurons are lost but also that 
substantial amounts remain in other striatal cells (Hefti et al., 1980), including glial 
cells (Li et al., 1992, Nakamura et al., 2000), inter- or efferent neurons (Hefti et al., 
1981, Melamed et al., 1981, Tashiro et al., 1989, Mura et al., 1995, Mura et al., 2000, 
Lopez-Real et al., 2003) and 5-HT terminals (Arai et al., 1996). Theoretically, L-DOPA 
can be converted to dopamine in all of these structures however only the 5-HT 
terminals express the VMAT needed for vesicular release of dopamine. Indeed, 
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substantial preclinical evidence suggests that the 5-HT terminals contribute to 
dopamine release in the dopamine denervated striatum (Tanaka et al., 1999, Navailles 
et al., 2010, Nevalainen et al., 2011). The finding that L-DOPA-induced dopamine 
output is nerve impulse-dependent (Miller and Abercrombie, 1999) and attenuated by 
reserpine pre-treatment (Kannari et al., 2000), further supports the role of the 5-HT-
terminals in this process. The dynamics of dopamine release in the absence of 
dopamine neurons is however altered, as the regulatory effects of the presynaptic D2 
receptors and the DAT are lost (Maeda et al., 1999, Miller and Abercrombie, 1999).  
 
1.3.2 L-DOPA 
The pharmacodynamic effects of L-DOPA are mediated by dopamine formed 
following decarboxylation (see Figure 3). L-DOPA can therefore be considered a 
prodrug. In the first clinical trials with L-DOPA a racemic mixture of D- and L-DOPA 
was used, the D-form is however not decarboxylated to dopamine and was additionally 
shown to induce hematologic side effects (Cotzias et al., 1967) and was therefore 
excluded. L-DOPA is taken per orally and is actively absorbed in the small intestine by 
the LNAA transporter. AADC is widely distributed in peripheral tissues such as the 
intestine and endothelial cells of the capillaries which allows for extracerebral 
formation of dopamine from the drug (Rahman et al., 1981). Indeed, inhibition of 
peripheral AADC was shown to increase central levels of catecholamines from L-
DOPA and to increase the locomotor stimulant effect of the drug in animals (Bartholini 
et al., 1967, Butcher and Engel, 1969). Dopamine in itself has poor availability over the 
BBB (Bertler et al., 1966, Oldendorf, 1971) but can access peripheral vascular 
dopamine receptors and receptors in the area postrema where the BBB is leaky. 
Peripheral conversion of L-DOPA to dopamine causes many of the side effects of the 
drug such as vomiting, nausea and ortostatic hypotension, which are reduced by co-
administration of L-DOPA with a peripheral AADC-inhibitor (PDI) such as carbidopa 
or benzerazide (Cotzias et al., 1969, Papavasiliou et al., 1972) (see Figure 3). The 
addition of a PDI improves the pharmacokinetics of L-DOPA by dramatically 
increasing the bioavailability and half-life, enabling a 75% reduction in the daily dose 
of L-DOPA needed to produce a clinical effect (Deleu et al., 2002). The plasma 
concentration of L-DOPA (+ PDI) reaches peak-values within an hour and the plasma 
half-life is short, approximately 1-2 hours (Nutt et al., 1985, Deleu et al., 2002). L-
DOPA is transported over the BBB using the LNAA for which there is a competition 
with other dietary amino acids (Alexander et al., 1994). In the CNS, L-DOPA is 
decarboxylated to dopamine and the relief of parkinsonian symptoms is achieved by the 
subsequent activation of postsynaptic dopaminergic receptors. Patients typically require 
400-500 mg L-DOPA/day which is administered in a preparation of 100/25 (L-DOPA 
and benserazide in mg respectively) taken four times daily.  
 
1.3.2.1 Therapeutic effects and side effects of L-DOPA  
L-DOPA is the single most effective agent to relieve the symptoms of PD (Goetz et al., 
2005). It efficiently controls the majority of motor symptoms of PD (Cotzias et al., 
1967), the exceptions being later onset motor symptoms such as freezing of gait and 
postural instability. L-DOPA improves quality of life, increases the time patients can 
manage on their own and, in addition, increases survival (Chen et al., 2006). Almost all 
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patients respond to L-DOPA treatment and initially enjoy a sustained improvement of 
motor function; this period is often referred to as the “honeymoon”. Patients are 
relatively unaware of fluctuations in the motor response in relation to the administration 
of a new dose of L-DOPA and the clinical response can outlast the fall in plasma levels 
of L-DOPA. This type of response which can be sustained even if an L-DOPA dose is 
missed is termed the long-duration response (LDR). The LDR is successively built up 
over days to weeks after the initiation of L-DOPA therapy and contributes substantially 
to the overall motor improvement produced by chronic treatment (Anderson and Nutt, 
2011). The LDR was first identified by the gradual deterioration in motor function 
occurring over several days following L-DOPA withdrawal (Cotzias et al., 1967, 
Muenter and Tyce, 1971). Over the time course of treatment and as the disease 
progresses the pharmacokinetics and pharmacodynamics of L-DOPA are altered and a 
short duration response (SDR) to L-DOPA becomes apparent (Nutt and Holford, 1996, 
Obeso et al., 2000a, Deleu et al., 2002, Nutt, 2003, 2008, Olanow et al., 2009b, 
Anderson and Nutt, 2011). The SDR is a measure of the duration of benefit from one 
single dose of L-DOPA (Olanow et al., 2009b); it closely parallels plasma levels of L-
DOPA and sets in within minutes following drug administration (Nutt et al., 1992, 
Contin et al., 1994). The SDR is measurable from the start of L-DOPA treatment but 
may be too subtle to be noticed by the patient and is then masked by the LDR (Olanow 
et al., 2009b, Anderson and Nutt, 2011). The emergence of an apparent SDR, however, 
marks the onset of motor fluctuations and dyskinesias which develop in as many as 70-
80% of patients following long-term treatment (Ahlskog and Muenter, 2001). Motor 
fluctuations are characterized by an apparent improvement of motor function “ON” 
following each given dose of L-DOPA and an apparent decline in motor ability “OFF” 
between dosing intervals. This type of fluctuating response is termed wearing off 
phenomenon or end-of-dose deterioration. Another type of motor fluctuation which 
commonly appears later on is the ON/OFF phenomenon with rapid and unpredictable 
transitions between “ON” and “OFF” states without apparent correlation to L-DOPA 
levles. The most common form of dyskinesia occurs when plasma concentrations of L-
DOPA peak and is therefore termed peak-dose dyskinesia. Peak-dose dyskinesia is 
abnormal involuntary, jerky movements with a dance-like pattern which are viewed as 
a sensitized response to therapy. Diphasic dyskinesias are characterized by ballistic 
movements of the legs which occur when L-DOPA levels are increasing or decreasing. 
Dyskinesias can also present as prolonged muscle spasms/dystonia (Obeso et al., 
2000a). The degree of dyskinesia determines the impact it has on the quality of life; 
mild dyskinesias can even be preferred to being in an “OFF” state. Severe dyskinesia 
however has a dramatic negative influence on several aspects of daily life such as social 
interaction, mobility, and balance (Encarnacion and Hauser, 2008). The risk factors for 
developing motor fluctuations and dyskinesias are duration and severity of disease and 
dosage and duration of L-DOPA treatment (Schrag and Quinn, 2000). Thus, patients 
with an early disease onset (Quinn et al., 1987) and patients treated with high doses of 
L-DOPA (Fahn, 2005, Sharma et al., 2006, Sharma et al., 2008) are much more likely 
to develop motor complications. Motor fluctuations often precede the onset of 
dyskinesias and therefore also represent a risk factor (Encarnacion and Hauser, 2008). 
The mechanism behind the shift from a stable to a fluctuating response accompanied by 
dyskinesias remains unknown. The peripheral pharmacokinetics of the drug remains 
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unaltered during the course of treatment (Gancher et al., 1987, Nutt et al., 1992). 
Therefore changes in the central kinetics of L-DOPA, dopamine release and the 
postsynaptic response have been suggested (see section 1.3.4). Patients who experience 
motor fluctuations and peak-dose dyskinesias are not easily managed and represent a 
major clinical challenge, as both the motor benefit and dyskinesias seem to depend on 
L-DOPA dosage. Thus manipulations to reduce dyskinesias also reduce the 
symptomatic effect, indicating a narrowing of the therapeutic window. The existence of 
a therapeutic window in severely dyskinetic patients has even been questioned i.e. the 
threshold concentration for anti-parkinsonian effect and dyskinesia are suggested to be 
similar or identical (Nutt, 2008). The occurrence of motor complications as a side effect 
to L-DOPA treatment was observed in the early trials of the drug (Cotzias et al., 1969, 
Yahr et al., 1969), therefore several other treatment strategies evolved to prevent or 
reduce their incidence. A brief description of these, in chronological order of 
introduction, follows below. It should however be mentioned that none of the newer 
agents have replaced the use of L-DOPA, but may provide substantial benefit as initial 
monotherapy or adjunct treatment to reduce motor complications. 
 
1.3.3 Other pharmacological agents for PD  
1.3.3.1 Dopamine receptor agonists  
Dopamine receptor agonists, generally called dopamine agonists, are routinely used as 
monotherapy and adjunct treatment to L-DOPA and provide symptom relief by directly 
activating dopamine receptors. The dopamine agonists used in PD-treatment differ in 
their pharmacokinetic and pharmacodynamic profile (Deleu et al., 2002, Nyholm, 
2006) but mainly activate dopamine D2 receptors. Dopamine agonists have several 
potential advantages over L-DOPA; the longer half-lie will provide increased duration 
of the therapeutic effect and the direct action at dopamine receptors eliminates the need 
of the enzymatic machinery. The ergot-derivate bromocriptine was first introduced as 
adjuvant treatment to L-DOPA in the 1970s (Calne et al., 1974) and was later followed 
by several other ergot derivates. The use of ergot derivates is however limited by their 
adverse event profile including cardiac valve fibrosis (Rascol et al., 2004) and has thus 
largely been replaced by the newer non-ergot derivates such as pramipexole and 
ropinirole. Dopamine agonists have been shown to induce significantly less dyskinesias 
as compared to L-DOPA (Rinne et al., 1998, Parkinsonstudygroup, 2000, Rascol et al., 
2000, Bracco et al., 2004, Holloway et al., 2004, Oertel et al., 2006) and to efficiently 
reduce motor fluctuations by reducing “OFF” time (Lieberman et al., 1998, Pinter et al., 
1999). Once L-DOPA treatment is initiated patients are at the same risk of developing 
dyskinesias but the onset is significantly delayed (Rascol et al., 2006). There have also 
been reports on a disease modifying i.e. neuroprotective effect of dopamine agonists 
(Parkinsonstudygroup, 2002, Whone et al., 2003) but there is yet no consensus on the 
matter (Ahlskog, 2003). Subcutaneous injections of apomorphine, a short acting D1 
and D2 agonist with rapid onset is used to provide a quick rescue from disabling ”OFF” 
states (Stibe et al., 1988). In similarity to L-DOPA administration, dopamine agonists 
induce nausea, vomiting and orthostatic hypotension. Dopamine agonists, however, 
have a higher propensity to induce somnolence, hallucinations and impulse control 
disorders as compared to L-DOPA (Olanow et al., 2009b). The benefit provided by 
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dopamine agonists with regards to motor fluctuations and dyskinesias make them an 
attractive first hand choice in PD-treatment, especially in young-onset PD patients.  
 
1.3.3.2 MAO-B inhibitors  
MAO-inhibitors increase brain levels of catecholamines by inhibition of their 
metabolism (see Figure 3). Non-selective, irreversible MAO-inhibitors were introduced 
as antidepressants in the 1950’s, but have been replaced by other agents due to their 
harmful cardiovascular side effects, the “cheese effect”. MAO-A is preferentially 
involved in the metabolism of dietary amines such as tyramine. Inhibition of the 
enzyme can cause accumulation of tyramine which displaces noradrenaline in the 
sympathetic nerve terminal thereby causing hypertensive crisis (Horwitz et al., 1964). 
Reversible inhibition of MAO-A or selective inhibition of MAO-B can be used to 
circumvent the “cheese effect”. Moclobemide, a reversible inhibitor of MAO-A, is 
currently used for treating depression but may also have beneficial effects in PD 
patients (Youdim and Weinstock, 2004). The irreversible MAO-B-inhibitors selegiline 
and rasagiline are routinely used in PD. Selegiline (L-deprenyl), developed by Knoll 
and colleagues (Knoll et al., 1965), was the first inhibitor to be evaluated for PD 
treatment (Birkmayer et al., 1975). Selegiline potentiates the symptomatic effect of L-
DOPA (Birkmayer et al., 1975, Heinonen and Rinne, 1989), reduces the dose of L-
DOPA needed for symptom relief (Larsen et al., 1999, Pålhagen et al., 2006) and 
reduces motor fluctuations (Ives et al., 2004). Selegiline was also found to have mild 
symptomatic effects and can be used as monotherapy early on in the disease 
(Parkinsonstudygroup, 1993). The clinical effectiveness of selegiline is mainly 
attributed to decreased metabolism of dopamine in the CNS (Riederer and Youdim, 
1986). Other effects, such as stimulated release via PEA (Paterson et al., 1991) or the 
active metabolites l-metamphetamine and l-amphetamine (Reynolds et al., 1978, 
Karoum et al., 1982) as well as blocked re-uptake of dopamine (Lai et al., 1980, Azzaro 
and Demarest, 1982, Fagervall and Ross, 1986) have also been suggested to contribute. 
Rasagiline is another, more potent MAO-B inhibitor which has similar effects as 
selegiline. It is effective as monotherapy and reduces motor fluctuations as adjunct to 
L-DOPA (Stocchi et al., 2008).  
 
MAO-B inhibitors have attracted much attention due to their possible neuroprotective 
effects. The potential for neuroprotection was spurred by the finding that MAO-B was 
involved in the neurotoxic effects of MPTP (Chiba et al., 1984) and that selegiline, via 
the inhibition of MAO-B, protected dopaminergic neurons from MPTP toxicity (Cohen 
et al., 1984, Heikkila et al., 1984). Both selegiline and rasagiline have been shown to 
slow down the progression of motor disability in clinical trials (Parkinsonstudygroup, 
1993, Palhagen et al., 2006, Olanow et al., 2009a) Despite these promising results the 
issue of neuroprotection is not firmly established (Fox et al., 2011) and the mechanism 
by which MAO-B-inhibitors would meditate neuroprotection remains elusive (Tatton 
and Chalmers-Redman, 1996, Olanow et al., 2009b). Due to their potential 
neuroprotective effects and mild symptom relief MAO-B inhibitors provide an 
attractive treatment strategy for early PD and are also useful as adjuncts to reduce 
motor fluctuations in advanced stages of the disease.  
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1.3.3.3 COMT inhibitors 
COMT inhibitors were introduced in the 1990s and used as adjunct treatment to the 
standard formulation of L-DOPA and a PDI.There are two COMT inhibitors available, 
entacapone and tolcapone. The peripheral metabolism of L-DOPA is mainly carried out 
by AADC, following blockade of this enzyme the L-DOPA is readily metabolized by 
COMT. COMT inhibitors act by inhibiting peripheral conversion of L-DOPA to 3-O-
methyldopa (3-OMD) (see Figure 3), thereby increasing its bioavailability, plasma half-
life and delivery to the CNS (Kaakkola, 2000). The addition of entacapone to L-DOPA 
was shown to increase the plasma half life of L-DOPA to two and a half hours (Nutt et 
al., 1994). Tolcapone has been shown to penetrate the BBB in animals studies 
(Forsberg et al., 2003) and could thus potentially increase central levels of L-DOPA 
and reduce the conversion of dopamine to 3-MT (see Figure 3).Tolcapone has been 
associated with liver toxicity (Olanow, 2000) and therefore liver function has to be 
monitored during its use. Addition of COMT inhibitors to L-DOPA effectively 
increases ON-time thereby preventing motor fluctuations and wearing off but may 
increase the risk for expression of dyskinesias if the dose of L-DOPA is not reduced 
(Lees, 2008). The addition of entacapone to L-DOPA in early PD-patients was not 
shown to reduce the development of dyskinesias (Stocchi et al., 2010). COMT 
inhibitors are therefore mainly used as adjuncts to L-DOPA to reduce motor 
fluctuations.  
 
1.3.4 Mechanisms underlying motor complications and their 
management 
As previously mentioned L-DOPA provides superior symptomatic control but the 
treatment is complicated by the high degree of motor complications. A major challenge 
in PD research is thus to find strategies to prevent or reduce L-DOPA-induced side 
effects by identifying the mechanisms underlying their development and expression. 
Although central kinetics of L-DOPA appears to be crucial for the emergence of motor 
complications, the pathogenic mechanisms responsible for the development of motor 
complications remain elusive. The currently held view integrates both presynaptic and 
postsynaptic alterations in the nigrostriatal connection (Cenci and Lundblad, 2006, 
Olanow et al., 2006, Iravani and Jenner, 2011). 
 
1.3.4.1 Presynaptic mechanisms underlying development of motor complications  
Individuals treated with L-DOPA for many years who were misdiagnosed with PD 
never developed motor complications (Barbeau, 1969). Motor complications are 
however rapidly induced in MPTP-exposed, severely dopamine depleted, humans and 
monkeys treated with L-DOPA (Ballard et al., 1985, Pearce et al., 1995). Analogously, 
in experimental animals the development of dyskinesias was shown to depend on the 
extent of denervation (Schneider, 1989, Boyce et al., 1990b, Papa et al., 1994, Di 
Monte et al., 2000, Winkler et al., 2002). The integrity of the dopaminergic system 
therefore seems to be of paramount importance for the correct handling of exogenous 
L-DOPA, i.e. the synthesis and packing of dopamine in vesicles and subsequent 
physiological release of the transmitter (Olanow et al., 2006). As the dopaminergic 
neurons progressively decrease in number, the ability to buffer dopamine produced by 
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exogenous L-DOPA is thought to decline (Chase et al., 1988, Chase, 1998). As a 
consequence, dopamine release will largely be mediated by non-dopaminergic cells 
lacking the proper regulatory machinery for regulated release (Maeda et al., 1999, 
Miller and Abercrombie, 1999).The system becomes increasingly dependent on 
exogenously supplied L-DOPA and owing to L-DOPA’s short half-life the levels of 
dopamine will oscillate considerably between doses. These fluctuations are in sharp 
contrast to the relatively constant levels of dopamine in the normal striatum which is 
maintained by the tonic firing of SNpc neurons (Floresco et al., 2003, Grace, 2008). 
The constant activation of dopamine receptors is crucial for normal basal ganglia 
function (Obeso et al., 2000b) and intermittent pulsatile stimulation of dopamine 
receptors is thought to result in a cascade of maladaptive postsynaptic changes 
ultimately responsible for the expression of motor complications (Cenci and Lundblad, 
2006, Olanow et al., 2006). 
 
In addition, the degeneration of dopaminergic neurons has been shown to result in an 
excessive increase in extracellular dopamine following L-DOPA administration in 
dopamine-depleted animals as well as in PD patients (Abercrombie et al., 1990, Tedroff 
et al., 1996). It is not clear whether this excessive release is involved in the 
development or expression of dyskinesias but peak-dose dyskinesia is associated with 
high levels of striatal dopamine following L-DOPA administration in PD (de la Fuente-
Fernandez et al., 2004, Pavese et al., 2006) and the same phenomenon has been 
observed in animals (Meissner et al., 2006, Lee et al., 2008, Lindgren et al., 2010). 
 
1.3.4.2 Postsynaptic mechanisms underlying development of motor complications 
There is compelling evidence for postsynaptic sensitization in dyskinetic animals, 
especially in the D1-receptor expressing MSNs of the direct pathway. Cellular markers 
associated with the MSNs in the direct pathway such as prodynorphin mRNA and the 
precursor pre-proenkephalin B are up-regulated (Cenci et al., 1998, Winkler et al., 
2002, Henry et al., 2003, Aubert et al., 2007), D1 receptor signaling is increased 
(Picconi et al., 2003, Aubert et al., 2005, Santini et al., 2007, Westin et al., 2007) and 
the trafficking of the D1 receptor is altered (Guigoni et al., 2007, Berthet et al., 2009). 
These findings suggest that LID is associated with hyperactivity of the direct pathway 
MSNs with subsequent alterations in the firing pattern of the output structures of the 
basal ganglia and increased facilitation of movement (Cenci, 2007) (see Figure 1). 
Indeed, both GPi and SNr show abnormal firing patterns in dyskinetic patients and 
animals (Papa et al., 1999, Alonso-Frech et al., 2006, Meissner et al., 2006). 
Accordingly, GABA levels are increased in the SNr but not in the GPe in dyskinetic 
rats (Mela et al., 2007). The sensitized D1-signaling cascade indicates that activation of 
this receptor increases the risk for motor complications. In fact, dopamine D1 receptor 
antagonists have been shown to reduce dyskinesia (Westin et al., 2007). However, 
activation of the D1 receptor is of importance for the full symptomatic effect, therefore 
D1 receptor antagonists do not represent a viable strategy to reduce motor 
complications (Grondin et al., 1999).  
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1.3.4.3 Management of motor complications  
A therapeutic strategy in PD is to mimic the physiological stimulation of dopamine 
receptors, i.e. to provide continuous dopaminergic stimulation and thereby reduce the 
risk for motor complications (Chase et al., 1989, Olanow et al., 2006). Preclinical 
studies have shown that the half-life of the dopaminergic agent and mode of 
administration, continous versus ittermittent, is correlated to the risk for motor 
complications (Blanchet et al., 1995, Bibbiani et al., 2005a). Accordingly, patients 
treated with long-acting dopamine receptor agonists develop less motor complications 
as compared to patients treated with L-DOPA (Rinne et al., 1998, Bracco et al., 2004, 
Holloway et al., 2004, Oertel et al., 2006). In order to delay the development of 
dyskinesia, treatment is often initiated with a dopamine agonist or an MAO-B inhibitor, 
especially in younger patients (Olanow et al., 2009b). COMT inhibitors have been 
shown to reduce dyskinesias in animal studies (Smith et al., 2005, Marin et al., 2006a) 
but this has not been confirmed in patients (Stocchi et al., 2010), which could possibly 
relate to the fact that this dose regimen still allows levels of L-DOPA and dopamine to 
fluctuate (Kuoppamaki et al., 2009). 
 
Once they appear motor fluctuations can be controlled by adding a dopamine agonist 
(Lieberman et al., 1998, Pinter et al., 1999), a COMT-inhibitor (Lees, 2008) or an 
MAO-B inhibitor (Stocchi et al., 2008), by subcutaneous injections or infusions of 
apomorphine (Pietz et al., 1998) or continuous infusion of L-DOPA (Nyholm and 
Aquilonius, 2004). Established dyskinesias are not easily managed as adjunctive 
treatment with dopamine agonists, COMT-inhibitors and MAO-B inhibitors may 
worsen dyskinesas and strategies to reduce dyskinesias typically worsen Parkinsonism 
(Encarnacion and Hauser, 2008). Infusion therapies with L-DOPA or apomorphine 
have however been reported to reduce the occurrence of pre-existing dyskinesias 
(Katzenschlager et al., 2005, Eggert et al., 2008). Amantadine was initially used as an 
antiviral agent and discovered to provide benefit against tremor and akinesia in PD-
patients (Schwab et al., 1969). Amantadine is the only clinically used pharmacological 
agent with reported anti-dyskinetic effects (Verhagen Metman et al., 1998, Del Dotto et 
al., 2001). The antidyskinetic properties of amantadine may be attributed to antagonism 
of NMDA receptors which are implicated in striatal plasticity (see section 1.4.2). The 
use of amatadine is however limited by cognitive side effects. Clozapine is an atypical 
antipsychotic agent used to treat drug-induced psychosis in PD-patients; it has also 
been shown to provide anti-dyskinetic effects but is not routinely used (Pierelli et al., 
1998, Durif et al., 2004).  
 
As most PD patients eventually require L-DOPA throughout the course of their 
treatment, much effort is made to further unravel the mechanisms which underlie the 
development of LID and to identify novel treatments to improve motor complications. 
The available animal models to study LID and novel experimental approaches derived 
from these will subsequently be discussed. 
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1.4 L-DOPA-INDUCED DYSKINESIA (LID) 
1.4.1 Animal models of LID 
Animal models of PD have provided an invaluable tool in the development of 
therapeutics for treatment of PD symptoms such as L-DOPA (Carlsson et al., 1957). In 
addition, models of PD have contributed to the understanding of the pathogenic 
mechanisms involved in the development of motor complications. There are several 
different ways to mimic the dopamine deficiency in PD in order evaluate the effects of 
anti-parkinsonian therapies (Duty and Jenner, 2011), whereas the study of motor 
complications has been successfully performed in two models based on a toxic insult to 
catecholaminergic neurons following administration of the selective neurotoxins 6-
hydroxydopamine (6-OHDA) or MPTP. These models mimic the permanent loss of 
dopamine which causes the motor symptoms of PD and thereby confer face validity. 
 
1.4.1.1 The 6-OHDA model 
In the late sixties Ungerstedt showed that intracerebral injections of 6-OHDA into 
catecholamine rich regions of the rat brain caused depletion of dopamine and 
noradrenaline (Ungerstedt, 1968). 6-OHDA is structurally similar to dopamine, with 
the exception of the hydroxyl group, and is taken up into dopaminergic and 
noradrenergic neurons by their respective transporter to accumulate within the cytosol. 
The mechanism by which 6-OHDA destroys catecholaminergic neurons is not 
completely understood, but it involves oxidative stress induced by ROS formed from its 
autoxidation (Sachs and Jonsson, 1975) and direct inhibition of mitochondrial 
complexes (Glinka and Youdim, 1995). 6-OHDA is administered via intracerebral 
injections since it does not cross the BBB. The injection sites and amounts can be 
varied to reproduce different stages of the disease. The unilaterally lesioned or 
“hemiparkinsonian” model is preferred since bilateral injections of 6-OHDA negatively 
influences feeding-behavior (Dunnett et al., 1983). In the present thesis work the toxin 
was injected in the median forebrain bundle (MFB) along which all forebrain 
monoaminergic projections run, this procedure results in  ≈ 95% reduction of striatal 
dopamine and may be suggested to model a very late stage of PD. The dopaminergic 
imbalance between the lesioned and intact striatum is manifested in a rotational 
behavior and animals rotate away from the hemisphere with dominant activation 
(Ungerstedt, 1976). The direction of turning is classified with reference to the lesioned 
striatum i.e. ipsi- and contralateral rotation. Ipsilateral rotation predominates in the 
untreated animal and reflects the dominant activation of the intact striatum. Systemic 
administration of amphetamine will act exclusively on the intact side and increases 
ipsilateral turning intensity (Zetterström et al., 1986). Contralateral rotation, on the 
other hand, is induced by L-DOPA and dopamine agonists and is thought to reflect 
activation of supersensitive dopamine receptors (Ungerstedt, 1971) (see Figure 4). This 
functional asymmetry can be used to evaluate the effects of symptomatic treatments by 
measuring the elicited rotational activity (Schwarting and Huston, 1996). The animals 
also develop asymmetry in the use of the limbs which is seen as difficulties in adjusting 
posture and to move during spontaneous behaviors such as grooming, exploration and 
walking (Cenci et al., 2002). These deficiencies are used to pharmacologically evaluate 
anti-parkinsonian effects in the cylinder and rotarod tests.  
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The unilateral model of PD was further developed by the Cenci-group as a means to 
study LID (Cenci et al., 1998). Rats express abnormal involuntary movements (AIMs) 
following L-DOPA administration and these affect the orofacial region, the trunk of the 
body and the limbs. AIMs are characterized by their purposeless, repetitive pattern 
which interferes with physiological motor activities. Rodent AIMs bear resemblance to 
peak-dose dyskinesias observed in humans although they differ by their species specific 
motor repertoire (Cenci et al., 2002). The development/expression of AIMs is 
dependent on dopaminergic lesion extent (Winkler et al., 2002) and in similarity with 
patients the severity increases with the L-DOPA dose (Lindgren et al., 2007). The 
model has been additionally validated by screening drugs with low liability to induce 
dyskinesias and drugs known to elicit anti-dyskinetic effect in primates (Lundblad et 
al., 2002, Dekundy et al., 2007). The scoring of rodent AIMS thus represent a widely 
used preclinical screening model for putative anti-dyskinetic agents.  
 
Figure 4. Rotational behavior in the unilateral 6-OHDA lesion model. 6-OHDA is injected in the right 
hemisphere, the motor system is crossed at the level of the medulla and the left side of the rodent body 
will therefore display motor deficits. The asymmetry can be observed as a rotational behavior and the rat 
will rotate away from the hemisphere with the dominant activation. In the untreated state, the rat rotates 
away from the left hemisphere and the rotation is directed towards the right lesioned striatum, ipsilateral 
rotation. Amphetamine stimulates dopamine release from presynaptic dopaminergic terminals in the 
intact striatum and further increase ipsilateral rotation. Administration of L-DOPA reverses the rotational 
behavior and animals rotate away from the lesioned side, rotation is thus directed towards the left intact 
hemispehere, contralateral rotation.Modified from (Schwarting and Huston, 1996). 
 
1.4.1.2 The MTPT-model 
The non-human primate MPTP model was developed following the observation that 
this toxin produced irreversible parkinsonism in humans (Langston et al., 1983). MPTP 
it is metabolized to MPP
+
 by MAO-B (Chiba et al., 1984), which is taken up into 
dopaminergic neurons (Javitch et al., 1985) where it interferes with the mitochondrial 
complex 1 (Nicklas et al., 1985). MPTP can be administered systemically and is able to 
penetrate the BBB. The toxin can also be used in some mice strains but has limited 
effects in rats. MPTP-treated monkeys exhibit motor features similar to PD patients i.e. 
bradykinesia, rigidity, tremor and postural instability as well as dyskinesias arising 
from chronic L-DOPA treatment (Boyce et al., 1990a, Langston et al., 2000). The 
MPTP-model is predictive for symptomatic and anti-dyskinetic agents and is 
commonly used as the last step before taking a drug into clinical trial (Duty and Jenner, 
2011).  
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1.4.2 Novel experimental approaches to target LID  
The intricate interplay between the dopaminergic system and other basal ganglia 
modulators such as glutamate, serotonin, noradrenaline and adenosine in the regulation 
of basal ganglia output has led to an emerging interest of their involvement in motor 
complications (Brotchie, 2005). Several strategies aimed at targeting non-dopaminergic 
systems as a means to provide symptomatic relief and/or reduce dyskinesias have been 
investigated (Fox et al., 2008) and the next section will therefore provide a brief 
overview of this area.  
1.4.2.1 Glutamate 
Increased glutamatergic transmission has been implicated in both the induction and 
expression of dyskinesas (Chase and Oh, 2000, Brotchie, 2005, Jenner, 2008). 
Glutamatergic neurons converge onto the MSNs and activate ionotropic NMDA and 
AMPA receptors as well as metabotropic glutamate receptors. Dopamine receptors 
modulate the gating and trafficking of glutamatergic NMDA and AMPA receptors via 
intracellular signaling cascades in the MSNs (see section 1.2.4.4). This functional 
interaction is affected by the pulsatile stimulation of dopamine receptors which occurs 
during chronic L-DOPA treatment (Chase and Oh, 2000) and various alterations in 
glutamate receptor function has been found in dyskinetic animals (Iravani and Jenner, 
2011). The sensitized response of the D1signaling cascade and the close interaction of 
this receptor and glutamate receptors (Conn et al., 2005, Fiorentini et al., 2008) further 
supports the notion that strategies targeting glutamatergic transmission may be 
beneficial in the treatment of dyskinesis. Indeed, the NMDA receptor antagonist 
amantadine alleviates dyskinesias in PD patients (Verhagen Metman et al., 1998, Del 
Dotto et al., 2001) and several preclinical studies have indeed shown beneficial effects 
of various glutamate antagonists on dyskinesia (Blanchet et al., 1998, Bibbiani et al., 
2005b, Mela et al., 2007, Rylander et al., 2009, Rylander et al., 2010a) (for review see 
(Iravani and Jenner, 2011)). 
1.4.2.2 Noradrenaline  
The noradrenergic system is involved in the pathophysiology PD as loss of 
noradrenergic neurons of the LC is commonly observed post mortem (Hornykiewicz 
and Kish, 1987, Zarow et al., 2003, Fornai et al., 2007, McMillan et al., 2011). The loss 
of noradrenergic neurons in PD is implicated in motor deficits, such as freezing of gait 
and postural instability, as well as in non-motor deficits, such as dementia, depression 
and impaired attention (Delaville et al., 2011).  
Although sparsely innervated, there is anatomical evidence for a noradrenergic 
projection to the striatum (Lindvall and Björklund, 1974, Mason and Fibiger, 1979, 
Jones and Yang, 1985) and to the substantia nigra (Jones and Yang, 1985). Adrenergic 
receptors are highly expressed in the basal ganglia system, the α2A-, α2C- and β1-
receptors are found in the striatum (Nicholas et al., 1996, MacDonald et al., 1997), and 
α2C-receptors have been localized to striatal MSNs of both the direct and indirect 
pathway (Holmberg et al., 1999). In the SN both α1-receptors (Jones et al., 1985) and 
α2C-receptors  (Lee et al., 1998) are expressed. Besides a modulation of the 
dopaminergic system at the somatodendritic and terminal level (Grenhoff et al., 1993, 
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Hertel et al., 1999, Gobert et al., 2004), noradrenaline may modulate postsynaptic 
signaling cascades in the MSNs via α2-receptor activation (Hara et al., 2010). Indeed, 
noradrenaline has been measured in the striatum in vivo (Cenci et al., 1992, Li et al., 
1998, Dawson et al., 2000, Gobert et al., 2004) and striatal noradrenaline release was 
found to be under the control of α2 receptors and to increase following administration 
of the selective noradrenaline reuptake inhibitor reboxetine (Gobert et al., 2004). 
Preclinical studies in animal models of PD suggest that the noradrenergic system may 
be implicated in LID. This conclusion is derived from the finding that α2-receptor 
antagonists may provide an antidyskinetic effect without interfering with the 
antiparkinsonian effect of L-DOPA (Gomez-Mancilla and Bedard, 1993, Henry et al., 
1999, Grondin et al., 2000, Fox et al., 2001, Savola et al., 2003, Johnston et al., 2010). 
However, the mechanism by which α2-antagonists mediate an anti-dyskinetic action 
remains elusive but may involve attenuation of dopamine release from L-DOPA (Buck 
et al., 2010) and/or modulation of GABA release in the basal ganglia nuclei (Zhang and 
Ordway, 2003, Alachkar et al., 2006). It is unclear wheter this latter effect is mediated 
via antagonism of postsynaptic α2-receptor activation by the endogenous ligand or via 
blockade of presynaptic auto-inhibitory receptors resulting in increased terminal release 
of noradrenaline (Gobert et al., 2004). Despite some promising results in PD patients, 
idazoxan was not further investigated due to limiting side effects (Rascol et al., 2001).  
1.4.2.3 Serotonin  
The serotonergic system is involved in a complex regulation of the basal ganglia 
system and possibly in both the induction and expression of LID (Fox et al., 2009). The 
release of dopamine from the 5-HT terminals has been proposed to contribute to 
pulsatile stimulation of dopamine receptors and to the expression of LID (Carta et al., 
2007). Additionally, dyskinetic animals and patients show maladaptive plasticity in 5-
HT system with an increased sprouting of striatal 5-HT terminals (Rylander et al., 
2010b). Serotonergic autoreceptor agonists have been shown to dampen the release of 
dopamine from L-DOPA (Kannari et al., 2001, Lindgren et al., 2010) and to reduce the 
expression of dyskinesias (Carta et al., 2007, Munoz et al., 2008, Lindgren et al., 2010). 
Consistent with these findings, saritozan, a partial 5-HT1A-agonist, was shown to 
reduce dyskinesias in PD patients (Olanow et al., 2004b, Bara-Jimenez et al., 2005). In 
another study, saritozan was, however, not effective in this regard and higher doses of 
the drug were found to worsen Parkinsonism (Goetz et al., 2007).  
1.4.2.4 Adenosine 
A2A receptors, expressed in the indirect pathway MSNs, are functionally linked to D2-
receptors and antagonize their activation. A2A antagonists may thus provide 
symptomatic relief by increasing the responsiveness of the D2-receptor upon activation 
and subsequently reduce the activity in the indirect pathway (Ferre et al., 1997, Fuxe et 
al., 2007). In animal models of PD, A2A antagonists have been shown to increase the 
locomotor stimulant effect of dopaminergic drugs (Koga et al., 2000, Lundblad et al., 
2003) and to reduce the development of apomorphine-induced dyskinesias (Bibbiani et 
al., 2003). The potential anti-dyskinetic effect of A2A antagonists may involve D2 
receptor independent mechanisms (Fuxe et al., 2007). Istradefylline is an A2A 
antagonist that has been evaluated as adjunct to L-DOPA in PD patients; it was shown 
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to significantly reduce motor fluctuations but to slightly increase dyskinesias (Mizuno 
et al., 2010). Other clinical trials suggest that istradefylline may be useful to increase 
the symptomatic effect of a suboptimal dose of L-DOPA and thereby reduce the 
expression of dyskinesias (Bara-Jimenez et al., 2003).  
 
1.5 DEUTERIUM-L-DOPA 
1.5.1 Deuterium isotope effects  
Deuterium or “heavy hydrogen” is a non-radioactive, naturally occurring, stable isotope 
of hydrogen which contains an additional neutron; it is termed D or 
2
H. The higher 
mass of the deuterium atom, as compared to that of hydrogen, dramatically increases its 
bond strength/stability to carbon (C) which requires more energy to be cleaved. The 
rate of a chemical reaction involving the cleavage of a C-H bond can thus be 
significantly reduced if hydrogen is exchanged by deuterium and this is defined as a 
primary isotope effect. The magnitude of the primary isotope effect is estimated by 
comparing the rate of the deuterium and hydrogen reaction, respectively. However, 
deuterium substitutions adjacent to the active cleavage site may also alter the rate of a 
chemical reaction, these secondary isotope effects are generally lower in magnitude 
(Foster, 1985). Deuterium has been widely used as a tracer in studies of drug 
pharmacokinetics and metabolism as well as in studies of endogenous biological 
processes (Foster, 1985, Koletzko et al., 1997, Kushner et al., 1999). Deuterium 
substitutions have also been evaluated as a strategy to reduce drug metabolism and 
hence improve pharmacokinetic and pharmacodynamic properties (Foster, 1985, 
Kushner et al., 1999). While none of the earlier candidates made their way into the 
clinic, the use of deuterium substituted drugs is presently gaining increasing interest 
(Sanderson, 2009).  
 
1.5.2 In vitro isotope effects on dopamine metabolism and conversion 
to noradrenaline 
Deuterium has also been used as a tool to study enzyme kinetics (Cleland, 2005). An 
isotope effect in an enzyme catalyzed reaction indicates that the bond which involves 
cleaving of the deuterium atom is the rate-limiting step. MAO catalyzes the first step in 
the oxidative deamination of the α-carbon in the dopamine molecule by the removal of 
one hydrogen and the amine group, which generates an aldehyde, DOPAL. The 
enzyme ALDH abstracts the remaining hydrogen atom which is replaced by a hydroxyl 
group to form the corresponding acid DOPAC (see Figure 5). Using deuterium labeled 
amines, dopamine, serotonin and tyramine, it was shown that the rate-limiting step in 
MAO-metabolism is the removal of the α-carbon hydrogen atom (Belleau et al., 1960, 
Yu et al., 1981, Yu et al., 1982, Yu et al., 1986, Yu, 1988). The magnitude of this 
primary isotope effect was found to be in the range of 2, indicating that the rate of 
oxidative deamination of dopamine by MAO is twice as slow when the α-carbon is 
deuteriated. Secondary isotope effects in the MAO catalyzed reaction were also 
observed following substitution of the second hydrogen at the α-carbon in the 
dopamine molecule (Yu et al., 1986) and following β-substitutions in the kynuramine 
molecule (Belleau and Moran, 1963). 
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Figure 5. Oxidative metabolism of the α-carbon in the dopamine molecule is catalyzed in two steps by 
the sequential action of MAO and ALDH.  
 
The conversion of dopamine to noradrenaline involves the cleavage of a C-H bond and 
the introduction of a hydroxyl group at the β-carbon, a reaction catalyzed by the 
enzyme dopamine β-hydroxylase (DβH) (see Figure 6).This reaction takes place inside 
of noradrenergic vesicles following transport of dopamine by the VMAT(Cooper et al., 
2003). In vitro experiments have demonstrated that deuterium substitutions at β-carbon 
in the dopamine molecule may produce a large primary isotope effect on the rate of 
noradrenaline formation (Miller and Klinman, 1983). In addition, a secondary isotope 
effect on noradrenaline formation was found following α-carbon substitutions (Miller 
and Klinman, 1985). Taken together, deuterium substitutions in the dopamine molecule 
may significantly alter the rate of MAO and DβH activity via primary and secondary 
isotope effects.  
 
Figure 6. Conversion of dopamine to noradrenaline via β-carbon hydroxylation.  
 
1.5.3 Deuterium-L-DOPA 
Against the given background, describing the limitations of current L-DOPA therapy 
and the apparent sensitivity of dopamine metabolism and noradrenaline formation to 
deuterium isotope effects, the present work aimed to investigate the potential utility of 
deuterium substitutions in the L-DOPA molecule as a means to improve the central 
kinetics and efficacy of the drug. There are five isoforms of deuterium-L-DOPA, 
produced by different combinations of α- and β-carbon substitutions (see Figure 7), 
which could display different metabolic profiles depending on the degree of primary 
and secondary isotope effects. As previously mentioned, in the decarboxylation process 
the carboxyl group is removed by the enzyme AADC and deuterium substitutions on 
the α- or β-carbons of the L-DOPA molecule would be retained in dopamine formed 
from it. We therefore hypothesized that dopamine formed from decarboxylation of 
deuterium-L-DOPA, carrying a deuterium atom at the α-carbon, would be more 
resistant to metabolic degradation by MAO and display an increased brain half-life. As 
a consequence, deuterium-L-DOPA might provide a more sustained stimulation of 
dopamine receptors and possibly allow lower doses of the drug to be used. Such 
properties would ultimately be advantageous in the treatment of Parkinson’s disease. 
Similarly, dopamine formed from deuterium-L-DOPA carrying deuterium atoms at the 
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β-carbon might display a reduced rate of noradrenaline formation. Therefore, the 
present thesis work aimed to evaluate the structure-activity relationship of different 
deuterium-L-DOPA isoforms in vivo with regard to neurochemistry and motor behavior 
and to further investigate potential clinical benefits in an animal model of Parkinson´s 
disease.  
 
 
 
Figure 7. Molecular structure of L-DOPA. Deuterium is introduced at the α- and/or β-carbons which are 
retained in the dopamine molecule following decraboxylation of L-DOPA. There are two hydrogens 
available for substitution on the β-carbon and one on the α-carbon. The nomenclature of the L-DOPA 
isoforms is derived from the position and number of deuterium substitutions. 
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2 SPECIFIC AIMS OF THE STUDY  
 
The overall aim of the present study was to investigate if in vitro isotope effects on 
dopamine metabolism are significant following administration of deuterium-L-DOPA 
in vivo. The experiments were designed to specifically: 
 
1. Investigate the structure-activity relationship of different isoforms of deuterium-L-
DOPA on dopamine metabolism in the intact animal and motor behavior in the 
temporarily dopamine-depleted rat 
 
2. Investigate if chronic administration of deuterium-L-DOPA might prove 
advantageous over standard L-DOPA in an animal model of LID 
 
3. Compare the effects of deuterium-L-DOPA with the combination of standard L-
DOPA and a clinically used MAO-B inhibitor on dopamine metabolism and motor 
behavior in an animal model of Parkinson´s disease 
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3 MATERIAL AND METHODS 
 
3.1 ANIMALS  
Male albino rats from the Wistar strain were used in all experiments with the exception 
of the experiments described in Paper II where female Sprague-Dawley rats were used. 
Upon arrival from the distributor, animals were acclimatized to the novel environment 
for five days before the start of an experiment. The animals were housed under 
temperature and humidity controlled conditions, on a 12 hour light/dark cycle. Standard 
laboratory rat chow and tap water was available ad libitum. All efforts were made to 
minimize the number of animals used and their suffering. Experiments were approved 
by, and conducted in accordance with, local animal ethics committees. In vivo 
microdialysis and locomotor activity experiments were approved by the Stockholm 
North Committee on Ethics of Animal Experimentation, ethical approval numbers:  
N340/02, N338/05, N 28/09 and N211/04. Behavioral experiments performed during 
chronic L-DOPA treatment were approved by the Malmö-Lund Committee on Ethics 
of Animal Experimentation, ethical approval numbers:  M 249/05 and M 231/08. In 
vivo pharmacokinetic experiments were approved by the German Committee on Ethics 
of Animal Experimentation, ethical approval number: N 2443/06.  
3.2 EXPERIMENTAL DESIGN (PAPER I, II, III AND IV) 
In Paper I, four different isoforms of deuterium-L-DOPA were screened for isotope 
effects on striatal dopamine metabolism using in vivo microdialysis. The experiments 
were performed in two sets, each comparing two deuterium-L-DOPA isoforms to L-
DOPA. The effect of the drugs was studied on dopamine and DOPAC output in intact 
animals. In addition, the effect of α,β,β-D3-L-DOPA and β,β-D2-L-DOPA was 
compared to L-DOPA for locomotor activity in reserpinized rats.  
In Paper II, the acute and chronic effects of L-DOPA and α,β,β-D3-L-DOPA treatment 
were compared with regards to motor behavior in the 6-OHDA-lesioned rat. In the 
acute study, a dose-response curve was established using the L-DOPA-induced rotation 
test to quantify motor stimulation. A lower equipotent dose of α,β,β-D3-L-DOPA to L-
DOPA was established and subsequently included in the chronic treatment design. Four 
treatment groups were thus studied; L-DOPA, α,β,β-D3-L-DOPA (both equivalent and 
equipotent to L-DOPA) and vehicle. Animals were administered the different 
treatments once daily for three weeks. The anti-parkinsonian effect was evaluated by 
the cylinder and the rotarod tests while dyskinesia was scored using the AIMS test.  
In Paper III, the effects of α,β,β-D3-L-DOPA and L-DOPA alone or in combination 
with the MAO-B inhibitor selegiline were compared in 6-OHDA-lesioned animals. The 
animals were first evaluated for acute behavioral effects and, following a wash-out 
period, neurochemical effects were studied by means of in vivo microdialysis. 
Behavioral effects of the study drugs were evaluated by monitoring locomotor, rearing 
and rotation activity and neurochemical effects were studied by the simultaneous 
detection of striatal L-DOPA, dopamine, noradrenaline, DOPAC, 3-MT, HVA and 5-
hydroxyindole acetic acid (5-HIAA).  
Materials and Methods 
 
29 
 
In Paper IV, the effect of L-DOPA and α,β,β-D3-L-DOPA on striatal noradrenaline, 
dopamine and DOPAC were evaluated by means of in vivo mincrodialysis in intact 
rats.  
3.3 DRUGS 
3.3.1 Study drugs 
Four different isoforms of deuterium L-DOPA, in which deuterium had been 
introduced at the α- or β-carbon of L-DOPA (see Figure 7), were synthesized at 
ChiroBlock GmbH, Germany and provided by BiRDS Pharma GmBH, Germany. The 
purity of these isotopic variants of L-DOPA was confirmed by the manufacturer using 
gas chromatography and mass spectroscopy. L-DOPA was purchased from Welding 
GmbH, Germany. L-DOPA and deuterium-L-DOPA were dissolved in different 
strengths of acidic solution (0.06-0.6 M HCl) depending on the concentration of the 
drug and whether or not it was co-administered with a PDI. Prior to injection the drug 
solution was pH balanced with the equimolar amount of NaOH. 
Carbidopa (10 mg/kg; Paper I and IV; Welding GmbH, Germany) was dissolved 
following the same protocol as L-DOPA compounds and administered 30 minutes prior 
to their injection. Benserazide hydrochloride (7.5 mg/kg in Paper II and12 mg/kg, 
Paper III; Sigma-Aldrich, Sweden) was dissolved in saline and co-administered with L-
DOPA compounds. Selegiline (R-(-)-Deprenyl hydrochloride, Sigma-Aldrich, Sweden) 
was dissolved in saline. Amphetamine (D-amphetamine, Sigma-Aldrich, Sweden) was 
diluted in saline.  
3.3.2 Drugs used to induce experimental PD 
Reserpine, a generous gift from AstraZeneca, Sweden, was dissolved in a minimal 
amount of glacial acetic acid and further diluted to it final volume in 5.5% sucrose 
solution. 6-OHDA-HCL (Sigma-Aldrich, Sweden) was dissolved in saline containing 
0.02% ascorbic acid.  
3.3.3 Drugs used for sterotaxic surgery  
In Paper I, III and IV, animals were anaesthetized using a cocktail containing Hypnorm 
(fentanyl citrate 0.39 mg/kg and fluanisone 12.5 mg/kg, VetaPharma, United Kingdom) 
and midazolam 6.25 mg/kg (Hameln pharmaceuticals GmbH, Germany). In Paper III, 
rats were anaesthetized, by a mixture of fentanyl citrate (0.37 mg/kg, B. Braun, 
Germany) and medetomin-HCl (0.24 mg/kg, Orion Pharma, Finland). The local 
anaesthetic bupivacaine (Marcain 2.5 mg/ml, AstraZeneca, Sweden) was injected in to 
reduce pain. For post-operative analgesia the animals received an injection of 
buprenorphine (0.01 mg/kg, Temgesic, Schering-Plough, Belgium). Atropine (0.14 
mg/kg, Merck NM, Sweden) was administered to reduce parasympathetic activity. 
3.3.4 Other drugs  
Tetrodotoxin (Sigma-Aldrich, Sweden), a blocker of voltage-gated sodium channels, 
was diluted in physiological perfusion solution (Apoteksbolaget, Sweden) and 
administered to the striatum via reversed dialysis in order to verify the action potential 
dependent nature of dopamine and noradrenaline peaks.  
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3.4 IN VIVO MICRODIALYSIS (PAPER I, III AND IV) 
3.4.1 Surgery and microdialysis 
Briefly, concentrical dialysis probes, with an active dialysis length of 3.5 mm, were 
implanted under stereotaxic surgery. The coordinates used to target the striatum were 
(in mm relative to bregma and the dura mater) AP: +0.6, ML: -3.0, DV: -6.2 according 
to the atlas of Paxinos and Watson 4
TH
 or 6
TH
 edition. The probe was fixed to the skull 
with anchor screws and dental cement. Following surgery, the animals were housed 
individually. Dialysis experiments were conducted approximately 48 h after surgery in 
awake and freely moving animals. The probe was perfused by physiological perfusion 
solution (147 mM NaCl, 3.0 mM KCl, 1.3 mM CaCl2, 1.0 MgCl2 and 1.0 mM NaHPO4 
, pH 7.4). 
Apoteksbolaget, Sweden) at a steady flow rate of 2.5 l/min which was controlled by a 
microinfusion pump (Harvard Apparatus, USA). Dialysis occurred through a 
semipermeable membrane (Filtral AN69, Hospal Industrie, France) and dialysate was 
collected in 15 (Paper I) or 30 minute (Paper III and IV) intervals.  
3.4.2 Neurochemical analysis 
Dialysate samples were automatically injected onto a C-18 column (Paper I and IV, 
Supelcosil 150*4.6 mm, 3 µM; Paper III, Kinetex 150*4.6 mm, 2.6 µM) for separation 
by high performance liquid chromatograpy (HPLC). The loading and injecting modes 
of the injector (Valco Instruments, USA) were controlled by the Totalchrom software 
(PerkinElmer, USA). The mobile phase was delivered to the column by a HPLC pump 
(Model 2150, Pharmacia LKB, Sweden or Model 2250, Bischoff Chromatography, 
Germany) at a flow rate of 0.7-0.8 ml/min. In paper I and IV the mobile phase 
consisted of a sodium acetate buffer (55 and 61 mM respectively) which was pH 
adjusted with glacial acetic acid to 4-5. In Paper III the mobile phase consisted of 
phosphate buffer (0.015 M) which was pH adjusted with phosphoric acid to ≈3. The 
mobile phases additionally contained methanol (10-13%), EDTA (0.01-0.03 mM) and 
heptanesulfonic or octanesulfonic acid. The online quantification of dopamine, 
noradrenaline and metabolites was achieved by electrochemical detection. Following 
separation, dialysis samples were subject to sequential oxidation and reduction in an 
analytical cell (ESA model 5011, Thermo scientific, USA) and the respective potentials 
(+ 400 mV and – 200 mV in Paper I and IV; + 250 mV and – 300 mV in Paper III) 
were controlled by a potentiostat (Esa Coulochem II or III, Thermo scientific, 
USA).Treatment was usually initiated following approximately 3-4 hours of dialysis 
when the baseline levels had stabilized (< 10 % variation).  
3.4.3 Histological verification of probe placement 
Following dialysis experiments, the rats were administered an overdose of sodium 
pentobarbital (≈120 mg/kg i.p., Apoteket AB, Sweden). In Paper I and IV the brain was 
immediately dissected and fixated in a solution containing 4% formaldehyde and 25% 
sucrose until further sectioning. In Paper III the animals were transcardially perfused 
and the tissue was processed for further immunohistochemical analysis (see section 
3.5.1.2). All brains were cut on a microtome, sections showing tissue damage from the 
dialysis probe were mounted on superfrost slides, stained with neutral red and finally 
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dehydrated. The position of the dialysis probe was verified under light microscopy and 
compared to the rat brain atlas by Paxinos & Watson, 4
TH
 or 6
TH
 edition. Only animals 
showing probe damage in the striatum were included in the subsequent data analysis.   
3.4.4 Data analysis and statistics  
The experiments were analyzed in the TotalChrome software (PerkinElmer, United 
states) which generates peak area and height for each analyte and sample. The 
experimental data values were compared to those of a known analyte concentration and 
expressed as fmol/minute. In Paper II and IV basal concentrations of dopamine, 
DOPAC and noradrenaline (only Paper IV) were statistically compared between the 
treatment groups using one-way analysis of variance (ANOVA) and there were no 
significant differences between the groups. Therefore, data are presented and analyzed 
as the per cent change compared to baseline (the samples collected one hour preceding 
treatment). In Paper I, DOPAC/DA-ratios were calculated using the total output of 
DOPAC and dopamine, respectively. In Paper III, 6-OHDA lesioned animals were 
studied and extracellular concentrations of dopamine, noradrenaline, DOPAC, 3-MT 
and HVA were close to or below the detection limit of the assay at baseline. In fact, 3-
MT levels were only detected in three animals and basal levels of noradrenaline were 
never detected. The effect of drug treatment on dopamine and metabolites was 
therefore presented in absolute values. Blank values, i.e. concentrations below detection 
limit, were replaced by the lowest detectable value; dopamine 0.0027 fmol/min, 
DOPAC 0.053 fmol/min, 3-MT 0.0699 fmol/min and HVA 0.124 fmol/min. The 
existing basal values of dopamine, DOPAC and HVA were compared between 
treatment groups by means of one-way ANOVA and there were no significant 
differences between the groups. Basal levels of 5-HIAA were readily detectable and as 
no significant difference was found between treatment groups, data are presented and 
analyzed as the percent change compared to baseline (the samples collected one hour 
preceding treatment).Treatment effects over time were statistically compared by two-
way ANOVA and followed by the Newman-Keuls post hoc test for multiple 
comparisons (Paper I) or the Fishers Least significant difference post hoc test (Paper III 
and IV) when appropriate, i.e. when a significant time*treatment interaction was found 
in the ANOVA analysis. All statistical comparisons were calculated in the 
STATISTICA software (StatSoft, Inc. USA). The significance level was set to α=0.05 
in all tests. 
3.5 THE RESERPINE MODEL OF PD (PAPER I) 
Pharmacological treatment of PD is based on the seminal findings that L-DOPA was 
able to antagonize the akinetic effects induced by antipsychotic agent reserpine 
(Carlsson et al., 1957), which could be linked to restoration of central levels of 
dopamine (Carlsson et al., 1958). Reserpine inhibits vesicular storage of monoamines, 
dopamine, noradrenaline and 5-HT by inhibiting the VMAT (Schuldiner, 1994). 
Inhibition of vesicular storage causes depletion as the amines are catabolised in the 
cytoplasm; this phenomenon is observed as a rapid increase in metabolites following 
reserpine administration (Elverfors and Nissbrandt, 1991, Heeringa and Abercrombie, 
1995). The dose of reserpine administered in the present study, 5 mg/kg, has been 
shown to cause a profound depletion of striatal dopamine and 5-HT which persists after 
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24 hours (Elverfors and Nissbrandt, 1991, Heeringa and Abercrombie, 1995). 
Reserpine-treated rats show the cardinal motor features of PD i.e. tremor, rigidity and 
hypokinesia (Colpaert, 1987). Systemic administration of anti-parkinsonian agents to 
reserpinized animals will reverse akinesia and increase locomotor activity. 
Quantification of locomotor activity thus provides a means to compare the motor 
stimulant effects of different drugs. Rats were housed on a 12 hr reversed light-dark 
cycle (lights off at 07:00). The night before experiments, rats were pre-treated with 
reserpine (5 mg/kg) or vehicle. Locomotor experiments were performed 10-12 hours 
later (see section 3.7.1).  
3.6 THE 6-OHDA LESION MODEL OF PD (PAPER II AND III) 
Some methodological aspects of the 6-OHDA-model are provided in the Introduction 
(see section 1.4.1.1). The rats were anaesthetized and mounted in a stereotaxic frame. 
The skin was cut and a hole was drilled in the skull bone.  6-OHDA-HCL (3.5 µg/µl 
free base 6-OHDA in 0.02% ascorbic acid, Sigma-Aldrich, Sweden) was injected at 
two sites to target the MFB 2.5 µl at (I) A-P -4.4, M-L -1.2, D-V -7.8, (tooth bar at – 
2.4) and 2 µl at (II) A-P -4.0, M-L -0.8, D-V -8.0, (tooth bar at + 3.4) according to 
(Paxinos & Watson 6
TH
 edition). The needle was left in place for 2.5 and 2 minutes, 
respectively, after the two injections.  
3.6.1 Evaluation of 6-OHDA lesion extent  
It is important to confirm similar lesion extent between treatment groups as the 
dopaminergic system is protective for the expression of dyskinesias (Winkler et al., 
2002, Lundblad et al., 2004). In Paper II, lesions extent was behaviorally evaluated 
using amphetamine-induced rotation. Following completion of the behavioral 
experiments; the dopamine denervations was evaluated by tyrosine hydroxylase 
immunoreactivity or dopamine transporter binding. Only animals with ≥94% dopamine 
denervation were included in the subsequent statistical analysis. In Paper III, lesion 
success was evaluated by determination of basal concentration of dopamine in the 
lesioned striatum by means of dialysis. The cut off for inclusion in the study analysis 
was set to <0.04 fmol/µl (Lindgren et al., 2010). The brains were additionally evaluated 
for tyrosine hydroxylase immunoreactivity after completion of dialysis experiments.  
 
3.6.1.1 Amphetamine-induced rotation (Paper II) 
Systemic administration of amphetamine will stimulate dopamine release from the 
intact terminals and increase ipsilateral turning intensity (Zetterström et al., 1986). The 
animals were tested approximately one week after the lesion. The rotational response 
elicited by an injection of 2.5 mg/kg D-amphetamine (Sigma-Aldrich, Sweden) was 
quantified in an automated rotometer. The cut off rotational score was set to >5 
ipsilateral rotations (relative to the lesion) per minute, indicating >90% of striatal 
dopamine denervation (Winkler et al., 2002).  
 
3.6.1.2 Tyrsoine hydroxylase immunohistochemistry (Paper II and III) 
Animals were deeply anaesthetized with sodium pentobarbital (≈120 mg/kg i.p. 
Apoteksbolaget AB, Sweden) and transcardially perfused with saline followed by ice 
cold 4% paraformadehyde (Sigma-Aldrich, Sweden). The brain was dissected and 
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placed in 4% paraformaldehyde for 2 hours and then transferred to 20 % sucrose (1-3 
days). The brains were frozen on dry-ice and stored in -20⁰C until sectioning. Sections 
(40 µM Paper II; 30 µM Paper III) were cut on a freezing microtome and stored 
(cryoprotective solution at -20
o
C Paper I; 0.1 M PBS at 4
o
C Paper III) for further 
immunohistochemical analysis.  
A detailed description of the immunohistochemical procedure can be found in the 
supplementary material accompanying Paper II and Paper III. Briefly, sections were 
rinsed and endogenous peroxidase activity was blocked by incubation with 3% H2O2 in 
methanol (Paper II). Unspecific antibody binding was reduced by incubation in 5% 
goat serum (Paper II) or 10% BSA (Paper III) for 1 hour. The tissue was incubated with 
the primary polyclonal antibody rabbit anti-tyrosine hydroxylase (Paper II; 1:1000, Pel-
Freez Biologicals, United States, overnight) or (Paper III; 1:5000 AB152, Millipore, 
USA, 48 hours). Sections were further incubated with the secondary biotinylated 
antibody (Paper II; 1:200, goat anti-rabbit, Vector Lab, United States and Paper III; 
1:400, sheep anti-rabbit, Vectastain Elite ABC, Vector Laboratories, United States) for 
1 hour at room temperature. Following incubation, sections were rinsed and processed 
using standard avidin-biotin-horse radish peroxidase (1:1000 in 0.05 M PBS, 
Vectastain Elite ABC, Vector Laboratories, United States) assay for 1 hour at room 
temperature. The resulting peroxidase activity was detected employing 3´3´-
diaminobenzidine (DAB-kit, Sigma-Aldrich, Sweden). The tissue was finally mounted 
on glass slides and photographed for subsequent image analysis.  
3.6.1.3 Dopamine transporter radioligand binding (Paper II) 
Animals were euthanized with sodium pentobarbital (≈120 mg/kg, Apoteksbolaget AB, 
Sweden) followed by decapitation. The brains were rapidly dissected and frozen on dry 
ice. Sections (14 µM) were cut and collected throughout the striatum, thaw-mounted on 
superfrost slides and stored at -20
o
C. Slides were pre-incubated in 50 mM Tris-HCl 
(pH 7.5) for 20 minutes. Incubation with the radioligand (I
125
) RTI-55 (2200 Ci/mmol, 
50 pM, Perkin Elmer, Sweden) (Boja et al., 1992) was performed for 1 hour in Tris-
HCl (pH 7.5) with fluoxetine (10 µM Lilly, Sweden), to prevent binding to the 
serotonin transporter. To verify unspecific binding, one assay was performed with 
nomifensine (100 µM, Research Biomedicals International, Natick, United States). 
Sections were exposed to autoradiographic film (Kodak BioMax MR-1, Perkin Elmer, 
Sweden) together with [
14
C] Microscale (Amersham, England) for 1 day. The films 
were manually processed with Kodak GBX-developer and fixer (Sigma-Aldrich, 
Sweden) and scanned for image analysis.  
3.6.1.4 Image analysis  
Digital images of the brain sections were converted to grey scale the Image J software 
(free download at http://rsbweb.nih.gov/ij/) and inverted. The mean grey value from the 
intact and the lesioned side were measured and the background value was subtracted 
from both. The reduction of signal on the lesioned side as compared to the intact was 
calculated in percent.  
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3.6.1.5 Data analysis and statistics  
The treatment groups mean values for TH and DAT staining were compared by one-
way ANOVA and there was no significant difference between treatment groups 
(α=0.05). In Paper II, the mean reduction in DAT binding for all animals in included in 
the chronic treatment study was 96.1±0.15 and in Paper III, the mean loss of TH 
immunoreactivity in the lesioned striatum for all animals included in the study was 
97.6% ± 0.7.  
3.7 ACUTE MOTOR BEHAVIOR (PAPER I, II AND III) 
3.7.1 Locomotor activity (Paper I and III) 
The experiments were performed in open field Plexiglas boxes (70x70 cm and 35 cm 
high, Kungsbacka Mät och Reglerteknik AB, Sweden) in which each side was 
equipped with two rows of photocells (8 cells per row, lower level at 3 cm and the 
upper level at 13 cm) either emitting or receiving infrared light, forming a two layer 
grid of infrared light beams. A locomotor event was registered when two consecutive 
beam breaks occurred in the lower layer, and summarized automatically every five 
minutes. In Paper I, locomotor activity was measured in reserpinized animals 10-130 
minutes post administration of L-DOPA compounds. In Paper III, 6-OHDA-lesioned 
animals were continuously evaluated for locomotor activity during baseline (15 
minutes), selegiline/vehicle administration (60 minutes) and up to 135 minutes post 
administration of L-DOPA or D3-L-DOPA.  
3.7.2 Rearing activity (Paper III)  
Rearing activity was manually scored from video recordings of the experiments 
performed in locomotor activity chambers (see above).The separate scoring of the left 
and right paw during rearing activity will give an indication of the lesion-induced 
asymmetry and its potential normalization following treatment. The number of rearings 
performed using the left paw for support was evaluated as percent of the total number 
of rearings performed during baseline (15 minutes), vehicle/selegiline treatment (60 
minutes) and L-DOPA or D3-L-DOPA treatment (135 minutes).  
3.7.3 L-DOPA-induced rotation (Paper II and III) 
The phenomenology and terminology of rotation in the unilateral 6-OHDA-lesioned rat 
is described in the Introduction (see section 1.4.1.1 and Figure 4). In Paper II, a dose-
response curve of different doses of L-DOPA and D3-L-DOPA was established. The 
total number of contralateral rotations performed 0-180 minutes post-administration 
was quantified in automated rotometry bowls. In Paper III, rotation was evaluated in 
locomotor activity chambers and the number of rotations made contra- or ipsilateral to 
the lesioned side were scored manually during baseline (15 minutes), selegiline/vehicle 
administration (60 minutes) and up to 135 minutes post administration of L-DOPA or 
D3-L-DOPA.  
3.7.3.1 Methodological considerations  
The use of L-DOPA-induced rotation to evaluate anti-parkonsonian efficacy during 
chronic treatment is complicated by the fact that the behavior sensitizes i.e. an acute 
subthreshold dose of L-DOPA may become increasingly effective to elicit rotation 
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following repeated administration (Schwarting and Huston, 1996, Henry et al., 1998, 
Lundblad et al., 2002). This sensitized response has been suggested to represent a 
dyskinetic motor pattern (Henry et al., 1998). Moreover, it is not correlated to the 
behavioral outcome of chronic L-DOPA-treatment in other tests of physiological motor 
function (Lundblad et al., 2002). The drug-induced rotation test may therefore not be 
sensitive enough to discriminate between anti-akinetic and dyskinetic effects of a 
putative therapy (Marin et al., 2006b). During the course of chronic treatment, the anti-
parkinsonian effect of D3-L-DOPA and L-DOPA were therefore evaluated by the 
cylinder and rotarod tests in which performance is compromised by dyskinesias.  
3.7.4 Data analysis and statistics  
In Paper II, the dose-ratio for L-DOPA and D3-L-DOPA was graphically evaluated at 
50% of the rotational response induced by the highest drug doses 
administered.Time*treatment interactions were statistically evaluated using two-way 
ANOVA followed by post hoc test when appropriate (Newman-Keuls multiple 
comparisons test in Paper I; Fishers Least significant difference post hoc test in Paper 
III). In Paper III, the significant time effect obtained from locomotor activity 
experiments was further evaluated by separate t-tests. All statistical comparisons were 
calculated in the STATISTICA software (StatSoft Inc., USA) and the significance level 
was set to α = 0.05.  
3.8 MOTOR BEHAVIOR DURING CHRONIC TREATMENT (PAPER II) 
3.8.1 The cylinder test  
The cylinder test measures the spontaneous explorative behavior an animal performs in 
a novel environment. The animal explores the cylinder by standing on the hindlimbs, 
supporting itself with the forelimbs against the cylinder wall. The lesion creates a limb-
use asymmetry in supporting wall contacts, which can be restored by L-DOPA-
treatment (Lundblad et al., 2002). Rats were placed in a glass cylinder, without prior 
habituation, and videotaped for five minutes. Animals showing little tendency to 
explore were stimulated by quickly turning the lights on and off in the experiment 
room, by a mild shake of the cylinder or by quickly picking up the rat and place it back 
in the cylinder. The experiments were scored by a blinded observer, counting the 
number of supporting wall contacts made with the right and the left paw, and a limb-
use asymmetry score was calculated. Dyskinetic animals with severely disrupted 
explorative behavior were excluded from the analysis, based on the observation that the 
animal mostly remained on the cylinder floor preoccupied with involuntary movements 
during the five minute session. The rats were tested in the cylinder test once before the 
start of chronic-treatment, and once during. In the session performed during chronic 
treatment, the animals were tested 140 minutes post drug administration.  
3.8.2 The rotarod test 
The rotarod test measures the ability of the animal to remain on a rotating rod at 
accelerating speed. Performance in this test is sensitive to dopaminergic lesioning and 
is improved after L-DOPA treatment (Lundblad et al., 2003). Each training session 
consisted of three separate trials on the rotarod (Rotamex 4/8, Columbus Instruments, 
United states). Animals were placed on the rod which spun at a rate of 4 rotations per 
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minute and then gradually accelerated to 44 rotations per minute over 90 seconds. 
When the rat fell off the rod the trial was over and the time recorded. To keep the rats 
alert, they were tapped on the tail several times during the trial. The rats were trained 
on the rotarod one session per day on three consecutive days to obtain stable baseline 
performance before the start of chronic treatment. During the chronic treatment period, 
baseline performance off L-DOPA (6 hours after the last L-DOPA injection) and 
performance on L-DOPA was evaluated once every week. After the last treatment 
week, the rats were kept on a drug-free interval for two days and then re-tested on the 
rotarod at 20 and 140 minutes post injection of L-DOPA compounds.  
3.8.3 Scoring of abnormal involuntary movements (AIMs) 
Dyskinesias were evaluated by scoring the animals for AIMs (Lundblad et al., 2002, 
Cenci and Lundblad, 2007), twice weekly during the course of chronic treatment. The 
animals were put in plastic cages and observed for one minute every 20 minutes up to 3 
hours after drug administration. The rats were scored, by a blinded observer, for limb, 
axial and orolingual involuntary movements, (0= no dyskinesia, 1= dyskinesia <30 
seconds, 2= dyskinesia >30 seconds, 3= continuous dyskinesia that could be interrupted 
by an external stimuli, 4= continuous dyskinesia not interruptible by an external 
stimuli). The external stimulus applied was a pen tap in the cage floor.   
3.8.4 Data analysis and statistics  
All data, except for AIMs, were analyzed by two-way ANOVA followed by Newman-
Keuls test when appropriate i.e. a significant time*treatment interaction was found in 
the ANOVA analysis. AIMs data were analyzed by non-parametric statistics. 
Independent comparisons of single variables were performed with the Kruskal-Wallis 
ANOVA by Ranks followed by the Mann-Whitney U-test. Independent comparisons of 
multiple variables were performed with the Mann-Whitney U-test. Dependent 
comparisons were performed with the Friedman ANOVA followed by the sign-test. All 
statistical comparisons were calculated in the STATISTICA software (StatSoft, Inc. 
USA) and the significance level in all tests was set to α = 0.05.  
3.9 PERIPHERAL PHARMACOKINETICS OF L-DOPA AND α,β,β-D3-L-
DOPA (PAPER II) 
The peripheral decarboxylase inhibitor carbidopa was injected 30 minutes before the 
injection of L-DOPA or D3-L-DOPA (50 mg/kg). Approximately 1 ml whole blood per 
animal and sampling time was collected from the retrobulbar venous plexus under light 
ether anesthesia. Blood samples were collected before injection of L-DOPA or D3-L-
DOPA, and then at 2.5, 5, 10, 15, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300 and 360 
minutes post injection and processed to plasma. L-DOPA and D3-L-DOPA 
concentrations were determined in plasma samples using HPLC coupled to 
electrochemical detection. The lower detection limit of the assay was 20 ng/ml of L-
DOPA or D3-L-DOPA. Missing data points, values below the detection limit of the 
assay, were replaced by the mean values from animals in the same treatment group at 
that time point. Data was analyzed using repeated measures ANOVA. 
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4 RESULTS AND DISCUSSION 
 
4.1 STRUCTURE/ACTIVITY RELATIONSHIP OF DEUTERIUM 
SUBSTITUTIONS IN THE L-DOPA MOLECULE ON DOPAMINE 
OUTPUT AND METABOLISM  
As previously discussed, bonds between carbon and deuterium are more stable as 
opposed to bonds between carbon and hydrogen and may therefore produce primary 
and secondary isotope effects on the rate of an enzymatic reaction (see section 1.5). The 
α-carbon-hydrogen bonds are removed during metabolism of dopamine to DOPAC and 
the β-carbon-hydrogen bond is abstracted during conversion to noradrenaline (see 
Figure 5 and 6).The combination of different carbon-deuterium substitutions in the L-
DOPA molecule may thus produce different metabolic profiles. We first set out to 
evaluate structure-activity relationships of α- and β-substitutions on dopamine 
metabolism by screening the different isoforms of deuterium L-DOPA (see Figure 7). 
Using cerebral microdialysis, dopamine metabolism can be studied in vivo by 
monitoring extracellular levels of monoamines and metabolites. The effect of a high 
dose of the test compounds (50 mg/kg) were therefore evaluated on dopamine and 
DOPAC output in the striatum of intact animals. 
 
Figure 8. Effects of carbidopa (10 mg/kg i.p) + vehicle, L-DOPA (50 mg/kg i.p.), β,β-D2-L-DOPA (50 
mg/kg i.p.) or α,β,β-D3-L-DOPA (50 mg/kg i.p.) on A) striatal dopamine output, B) striatal DOPAC 
output and C) DOPAC/dopamine (DA) ratios. Data are expressed as per cent of baseline and presented as 
mean ± S.E.M. Arrows indicate the first and second injection, separated by 30 minutes.*=p<0.05, 
**=p<0.01, ***=p<0.001, α,β,β-D3-L-DOPA vs. L-DOPA, +=<0.05, β,β-D2-L-DOPA vs. L-DOPA.  
 
Interestingly, the first two isoforms evaluated, β,β-D2-L-DOPA and α,β,β-D3-L-
DOPA, produced opposing effects on dopamine metabolism (see Figure 8). β,β-D2-L-
DOPA gave rise to lower levels of dopamine and higher levels of DOPAC as compared 
to L-DOPA, thus suggesting an increased turnover of dopamine. In accordance 
herewith, the calculated DOPAC/dopamine ratio, which constitute an estimate of 
dopamine turnover, were higher than those observed following L-DOPA-treatment. 
These results suggest that the β-carbon substitutions alone increase MAO-mediated 
enzymatic degradation of the substrate.The mechanism responsible for this effect is 
unknown but has also been observed in vitro (Yu et al., 1982). α,β,β-D3-L-DOPA on 
the other hand produced an increase in dopamine outflow of similar magnitude as L-
DOPA, whereas the effect of α,β,β-D3-L-DOPA was dramatically prolonged, i.e. 
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extracellular levels of dopamine remained elevated for several hours. The levels of 
DOPAC were similar as those produced by L-DOPA while the DOPAC/dopamine ratio 
was significantly lower, indicating that the metabolism of dopamine formed from α,β,β-
D3-L-DOPA was reduced. The effect elicited by α,β,β-D3-L-DOPA confirmed our 
hypothesis of a significant in vivo isotope effect on dopamine metabolism and 
underlined the importance of the α-carbon deuterium atom to produce such an effect. In 
fact, the rate limiting step in dopamine metabolism is the removal of an α-carbon 
hydrogen, evidenced by the significant primary isotope effect in this reaction 
demonstrated in vitro (Yu et al., 1982, Yu et al., 1986, Yu, 1988). Our findings thus 
extend previous in vitro observations while contrasting the effects observed following 
administration of the racemic mix of deuterium-substituted DOPA (D,L- α,β,β-D3-L-
DOPA) in vivo (Dewar et al., 1985). The failure of the latter study to detect the 
differences observed herein are most likely due to the use of tissue homogenates to 
compare the effects of D,L- α,β,β-D3-L-DOPA and D-L-DOPA on striatal dopamine. 
Analysis of tissue levels of dopamine is a method that can not distinguish intra- and 
extracellular levels of dopamine and therefore differences in the dynamics between 
these compartments may not be detected. 
 
As β,β-carbon substitutions alone seemed to slightly increase MAO activity, we 
hypothesized that an isoform of L-DOPA labeled with deuterium only at the α-carbon 
could produce an even more pronounced effect on dopamine metabolism as compared 
to α,β,β-D3-L-DOPA. Thus, to evaluate if β-substitutions counteracts the effects of the 
α-carbon substitution, the effects of α-D1-L-DOPA and α,β-D2-L-DOPA were 
subsequently studied using the same protocol. Surprisingly, α-D1-L-DOPA did not 
increase dopamine output significantly and the levels of DOPAC were significantly 
reduced as compared to those observed following L-DOPA administration. α,β-D2-L-
DOPA produced intermediate effects that were similar to those produced by L-DOPA 
(see Figure 9). The lack of effect of α-D1-L-DOPA indicates that the single α-
deuterium substitution negatively influences other processes which are related to the 
availability of dopamine in the terminal. One hypothetical explanation is that the 
decarboxylation of α-D1-L-DOPA was reduced. The β-carbon substitutions thus seem 
necessary to counteract this effect. 
 
 
Figure 9 Effects of carbidopa (10 mg/kg i.p) +L-DOPA (50 mg/kg i.p.), α-D1-L-DOPA (50 mg/kg i.p.) 
or α,β-D2-L-DOPA (50 mg/kg i.p.) on A) striatal dopamine output,  B) striatal DOPAC output and C) 
DOPAC/DA ratios. Data are expressed as per cent of baseline and presented as mean ± S.E.M. Arrows 
indicate the first and second injection, separated by 30 minutes. .*=p<0.05, **=p<0.01, ***=p<0.001, α-
D1-L-DOPA vs. L-DOPA.  
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The altered effects of deuterium-substituted L-DOPA may potentially be related to 
differences in the uptake and elimination of the drug from the periphery. However, as 
evidenced by the plasma concentration measurements of L-DOPA and α,β,β-D3-L-
DOPA (see Paper II, supplementary material) the deuterium-substitutions in α,β,β-D3-
L-DOPA do not affect the peripheral pharmacokinetics of the drug.  
 
In summary, the potent effect observed following administration of α,β,β-D3-L-DOPA 
suggests that the combination of one deuterium substitution on the α-carbon and two on 
the β-carbon produce the most favorable in vivo isotope effects on dopamine 
metabolism. Thus, despite the slight enhancement of dopamine metabolism observed 
following β-carbon substitutions alone they seem necessary to stabilize the α-carbon 
substitution for an efficient presynaptic handling of deuterium L-DOPA in vivo. As the 
β-carbon is not directly cleaved by MAO, it may also contribute to produce secondary 
isotope effects on dopamine metabolism (Belleau and Moran, 1963), i.e. MAO activity 
is reduced by the deuterium substitutions surrounding the active cleavage site. This 
combination of deuterium substitutions in the dopamine molecule were never 
investigated in vitro, but studies using deuterium labeled 5-HT show a similar 
magnitude of the isotope effect on MAO metabolism from α,α,β,β-5-HT as for α,α-5-
HT (Yu et al., 1982). Our in vivo data suggest that the turnover of dopamine formed 
from α,β,β-D3-L-DOPA is reduced, which is observed as a prolonged neurochemical 
response following its administration.  
 
The observed acute effects of α,β,β-D3-L-DOPA on dopamine metabolism might be 
advantageous in the treatment of Parkinson’s disease. The increased half-life of 
dopamine formed from α,β,β-D3-L-DOPA may serve to reduce pulsatile stimulation of 
dopamine receptors and to extend the motor benefit from each dose of the drug, thereby 
enabling a prolongation of the dosing interval or a reduction in the dose of L-DOPA. 
Altogether, a reduced L-DOPA load and more sustained stimulation of dopamine 
receptors could improve L-DOPA treatment by reducing the risk for motor fluctuations 
and dyskinesias. Therefore, α,β,β-D3-L-DOPA was further investigated for 
neurochemical and behavioral effects in the 6-OHDA model of PD. Additionally, the 
effects of this isoform with regard to noradrenaline formation were compared to L-
DOPA. 
 
4.2 NEUROCHEMICAL EFFECTS OF α,β,β-D3-L-DOPA (PAPER I, III, IV) 
4.2.1 Effects on noradrenaline formation  
As L-DOPA is the precursor of both dopamine and noradrenaline, L-DOPA 
administration may significantly increase the output of noradrenaline Dopamine is 
transported into vesicles via the VMAT and is there converted to noradrenaline by the 
enzyme DβH which introduces a hydroxyl group at the β-carbon (see Figure 6). As the 
rate of DβH to produce noradrenaline from dopamine is subject to both primary and 
secondary isotope effects in vitro (Miller and Klinman, 1983, 1985), formation of 
noradrenaline from α,β,β-D3-L-DOPA may be significantly reduced as compared to L-
DOPA. Therefore, in the next round of experiments we investigated the effects of low 
dose (5 mg/kg) of α,β,β-D3-L-DOPA and L-DOPA on striatal noradrenaline and 
dopamine output in intact animals. Interestingly, L-DOPA administration significantly 
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increased striatal output of noradrenaline while α,β,β-D3-L-DOPA administration left 
basal levels of noradrenaline unaltered (see Figure 10 A). 
 
 
Figure 10. Effects of carbidopa (10 mg/kg i.p.)+L-DOPA (5 mg/kg i.p.) or α,β,β-D3-L-DOPA (5 mg/kg 
i.p) on A) striatal noradrenaline output, B) striatal dopamine output and C) striatal DOPAC output. Data 
are expressed as per cent of baseline and presented as mean ± S.E.M. Arrows indicate the first and second 
injection, separated by 30 minutes *p<0.05, **p<0.01 α,β,β-D3-L-DOPA versus L-DOPA; +p<0.05, 
++
p<0.01, 
+++
p<0.001 L-DOPA versus vehicle; 
¤
p<0.05, 
¤¤
p<0.01 and 
¤¤¤
p<0.001 D3-L-DOPA versus 
vehicle.  
 
In a recent microdialysis study L-DOPA (50 mg/kg) was found to increase striatal 
noradrenaline output (Bianco et al., 2008). The present results confirm these findings 
and show that also a lower dose of L-DOPA significantly increases striatal 
noradrenaline release. The opposing effects of α,β,β-D3-L-DOPA and L-DOPA on 
noradrenaline output are in all probability the result of delayed β-hydroxylation of 
deuterium dopamine by DβH, indicating a significant in vivo isotope effect in this 
reaction. This could also imply that the release of dopamine may be increased from 
noradrenergic terminals following administration of α,β,β-D3-L-DOPA. The reduced 
output of noradrenaline from α,β,β-D3-L-DOPA may prove to be of clinical importance 
(see section 5).  
 
4.2.2 Effects on dopamine output 
4.2.2.1 Intact animals  
Similar to the results observed after administration of high doses of L-DOPA and α,β,β-
D3-L-DOPA (Figure 8), a low dose (5 mg/kg) of α,β,β-D3-L-DOPA produced a 
prolonged elevation of dopamine outflow as compared to L-DOPA (Figure 10 B). In 
fact, even though L-DOPA produced a slight increase in extracellular levels of 
dopamine over baseline; this effect was not significant when compared to vehicle 
administration. Previous studies investigating the effects of L-DOPA on extracellular 
dopamine, in rats, have shown inconsistent results. While some have reported 
decreased or unaltered dopamine output following administration of 50 mg/kg of L-
DOPA (Abercrombie et al., 1990, Wachtel and Abercrombie, 1994, Miller and 
Abercrombie, 1999, Kannari et al., 2000) other studies, including the present, report 
increases using the same dose (Kaakkola and Wurtman, 1993, Fornai et al., 2000, 
Bianco et al., 2008) or even lower doses of the drug (Orosz and Bennett, 1992, Maeda 
et al., 1999, Lindgren et al., 2010). This discrepancy has elegantly been shown to relate 
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to the fact that peripheral AADC inhibitors may enter the CNS and dose-dependently 
inhibit the activity of striatal AADC (Jonkers et al., 2001). Studies showing more 
pronounced effects of L-DOPA on dopamine output have consistently administered 
lower doses of benserazide or the less potent inhibitor carbidopa.  
 
The enhanced effects of α,β,β-D3-L-DOPA on extracellular levels of dopamine 
indicate that the central kinetics of deuterium dopamine is altered. As in vivo 
microdialysis measures extracellular levels of dopamine, which represent the sum of 
release and clearance by re-uptake, metabolism and diffusion, from all cells 
surrounding the probe, it is not possible to dissect the exact mechanism by which α,β,β-
D3-L-DOPA produces this effect. However, as an altered activity of MAO towards 
deuterium dopamine is the most likely explanation for our findings, the theoretical 
mechanisms which underlie the patterns of extracellular dopamine observed can at least 
be partly understood. 
 
In general, dopamine release may occur via exocytotic vesicular release and via carrier-
mediated reversed transport of the cytosolic pool of dopamine (see secion 1.3.1.1). 
There is experimental evidence showing that both types of release may occur following 
L-DOPA administration in both intact and lesioned animals (Koshimura et al., 1992, 
Sarre et al., 1992, Mizoguchi et al., 1993, Sarre et al., 1994, Miller and Abercrombie, 
1999, Kannari et al., 2000). Dopamine released following L-DOPA administration may 
to a significant extent be controlled by the activity of MAO, which regulates the 
cytosolic concentration of the transmitter by an efficient metabolism of newly 
synthesized dopamine. Inhibition of MAO would thus increase the cytosolic pool of 
dopamine which stimulates carrier-mediated release (Levi and Raiteri, 1993) and 
additionally may increase the vesicular fraction of dopamine available for exocytotic 
release, as demonstrated in vitro (Buu, 1989). Thus, reduced intracellular clearance of 
dopamine formed from α,β,β-D3-L-DOPA by MAO can be predicted to increase both 
the cytosolic and vesicular pool of dopamine available for release, a that may explain 
the prolonged elevation of dopamine output observed following administration of 
α,β,β- α,β,β-D3-L-DOPA. This conclusion also derives support from studies showing 
that inhibitors of MAO-A, the exclusive isoform present in the dopaminergic neurons, 
increase L-DOPA-induced dopamine output in the intact striatum (Wachtel and 
Abercrombie, 1994, Brannan et al., 1995, Finberg et al., 1995).  
 
In addition to presynaptic mechanisms, the clearance of released deuterium dopamine 
by postsynaptic MAO-containing cells may be affected. Administration of a MAO-B 
inhibitior may allow for an indirect estimation of postsynaptic metabolism, as this 
isoform is localized at “extra-dopaminergic” sites. Under basal conditions MAO-B 
inhibition has no effect on dopamine levels in rats (Butcher et al., 1990, Colzi et al., 
1990, Wachtel and Abercrombie, 1994, Brannan et al., 1995, Lamensdorf et al., 1996, 
Fornai et al., 2000). However, following L-DOPA administration MAO-B inhibition 
significantly increases L-DOPA-induced dopamine output (Wachtel and Abercrombie, 
1994, Brannan et al., 1995). These findings illustrate the role of postsynaptic 
compartments in the regulation of extracellular dopamine, which may become 
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increasingly important under conditions of high substrate availability, such as following 
L-DOPA administration.  
 
In summary, α,β,β-D3-L-DOPA elevates extracellular levels of dopamine more 
efficiently than L-DOPA, an effect that in all likelihood may be attributed to reduced 
activity of MAO towards deuterium dopamine.The increase in extracellular levels of 
dopamine may reflect an altered presynaptic handling of deuterium dopamine inside of 
the MAO-A containing dopaminergic terminals, resulting in an enhanced release, as 
well as reduced clearance of released deuterium dopamine at MAO-A and -B 
containing postsynaptic sites (see Figure 3).  
 
4.2.2.2 6-OHDA-lesioned animals 
As discussed in the introduction the dynamics of dopamine formation and release are 
altered in the dopamine depleted brain (see section 1.3.1.4). For example, the 
metabolism of dopamine is shifted from the dopaminergic neuron to other striatal 
compartments. Surprisingly, neither MAO-A nor -B inhibition was found to affect 
striatal dopamine output following L-DOPA administration to 6-OHDA lesioned 
animals (Wachtel and Abercrombie, 1994). This finding indicates that the ability to 
alter dopamine output from L-DOPA by modulation of MAO activity is lost following 
severe degeneration on dopaminergic neurons, a conclusion which contrast the 
behavioral effects produced by α,β,β-D3-L-DOPA in this model (see section 4.3). 
Therefore, the neurochemical effects of α,β,β-D3-L-DOPA were subsequently 
investigated in the dopamine-depleted striatum. α,β,β-D3-L-DOPA administration was 
shown to produce an increased dopamine output in comparison with L-DOPA 
administration (see Figure 11A), indicating that the effects of the deuterium substitution 
on the dynamics of dopamine release and clearance remain in the almost complete 
absence of dopaminergic neurons. The temporal pattern of dopamine output was, 
however, altered as compared to that observed in intact animals (Figures 8 and 10). 
While the duration of dopamine output following α,β,β-D3-L-DOPA administration 
was not as pronounced in the lesioned animals, there was a significant effect on the 
magnitude of the increase as compared to L-DOPA. In similarity with the experiments 
performed in the intact animals, the effects of α,β,β-D3-L-DOPA may here be 
attributed both to increased release from the decarboxylating cell due to decreased 
MAO-metabolism and/or decreased metabolism of deuteriated dopamine following its 
release.  
 
There is compelling experimental evidence  showing that the release of dopamine from 
L-DOPA is carried out by 5-HT neurons in dopamine-depleted animals (Tanaka et al., 
1999, Navailles et al., 2010, Nevalainen et al., 2011). The role of presynaptic MAO in 
5-HT terminals to metabolize L-DOPA-induced dopamine is however unclear (Tanaka 
et al., 1999) and only sparse localization of MAO is found in the terminal areas of the 
5-HT system (Levitt et al., 1982, Westlund et al., 1988, Jahng et al., 1997, Arai et al., 
2002). If the 5-HT terminals do contribute to dopamine metabolism, it is probably 
mediated by MAO-A, since only MAO-A inhibition affects striatal metabolism of 5-
HT (Kato et al., 1986, Butcher et al., 1990, Stanley et al., 2007).  
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Figure 11. Neurochemical effects in the 6-OHDA lesioned striatum. Vehicle (1 ml/kg, s.c.) or selegiline 
(1 mg/kg, s.c.) were administered first, one hour later L-DOPA or α,β,β-D3-L-DOPA (3 mg/kg s.c., co-
administered with benzerazide 12 mg/kg) was injected. Arrows indicate time of injection. A. Dopamine. 
B. DOPAC. C. 3-MT. Data is presented as mean ±SEM.*p<0.05, **p<0.01,***p<0.001 vehicle/ α,β,β-
D3-L-DOPA versus vehicle/L-DOPA; +p<0.05, ++p<0.01, +++p<0.001 selegiline/L-DOPA versus 
vehicle/L-DOPA; ◊p<0.05 vehicle/D3-L-DOPA versus selegiline/L-DOPA; ¤p<0.05, ¤¤p<0.01, 
¤¤¤p<0.001 vehicle/ α,β,β-D3-L-DOPA versus selegiline/ α,β,β-D3-L-DOPA.  
 
In the same experiments, the effects of α,β,β-D3-L-DOPA and L-DOPA alone as well 
as in combination with the clinically used MAO-B inhibitor selegiline (see section 
1.3.3.2) on dopamine metabolism were compared. α,β,β-D3-L-DOPA and the 
selegiline/L-DOPA combination produced similar effects on dopamine output and 
these effects were significantly higher than in the group receiving L-DOPA alone. 
Given the presumption that 5-HT terminals release dopamine and lack MAO-B, we 
suggest that the effects produced by selegiline/L-DOPA administration was the result 
of a less efficient metabolism of released dopamine at MAO-B containing postsynaptic 
sites, i.e. astrocyte processes surrounding the synapses (Levitt et al., 1982, Westlund et 
al., 1988) and postsynaptic neurons (Finberg, personal communication). Moreover, 
selegiline pre-treatment did not potentiate the effects of α,β,β-D3-L-DOPA, a finding 
which suggests that the increased output of dopamine generated by α,β,β-D3-L-DOPA 
predominantly reflects a decreased metabolism of released dopamine and that this 
effect is mediated mostly via MAO-B. Against this background it can furthermore be 
concluded that the presynaptic contribution to the elevated dopamine levels observed 
following administration of α,β,β-D3-L-DOPA in dopamine-depleted rats should be 
rather small, which may explain the temporal difference between the effects of α,β,β-
D3-L-DOPA in intact versus lesioned animals.  
 
It should be noted that MAO-B inhibition has previously been shown not to affect 
dopamine levels following L-DOPA administration in the lesioned rat striatum 
(Wachtel and Abercrombie, 1994, Finberg et al., 1995). This discrepancy may be 
attributed to differences in the extent of the lesions or to the fact that the sensitivity of 
the assays used has been improved since the publication of the two previous studies.  
 
In summary, α,β,β-D3-L-DOPA produced an increase in dopamine output that was 
higher than the effect of L-DOPA in the lesioned striatum. This effect closely 
resembled that of L-DOPA in combination with selegiline. It is proposed that the 
increased concentration of extracellular dopamine mainly depends on reduced 
metabolism of released deuterium-dopamine at MAO-B containing postsynaptic sites.  
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4.2.3 Effects on dopamine metabolism 
4.2.3.1 DOPAC 
Our data consistently show increased levels of dopamine following α,β,β-D3-L-DOPA 
administration as compared to non-modified L-DOPA (Figure 8, 10 and 11), which is 
attributed to an altered activity of MAO towards deuterium dopamine. The effects of 
α,β,β-D3-L-DOPA on the MAO metabolite DOPAC were however less prominent. 
Since previous studies have shown that inhibition of MAO-A markedly reduces 
extracellular DOPAC levels in L-DOPA-treated animals (Wachtel and Abercrombie, 
1994, Brannan et al., 1995, Finberg et al., 1995) it would be expected that the elevated 
dopamine levels following α,β,β-D3-L-DOPA should be associated with a coincident 
decrease in extracellular DOPAC levels. When compared with effects of L-DOPA 
administration, reduced DOPAC levels were only observed following administration of 
a low dose of α,β,β-D3-L-DOPA in the intact striatum (see Figure 10 C). α,β,β-D3-L-
DOPA is, however, not likely to inhibit MAO per se, but rather to produce a delay in 
the metabolism of dopamine formed. Extracellular levels of DOPAC represent a 
measure of intracellular MAO metabolism of dopamine (Butcher et al., 1988, 
Zetterström et al., 1988, Eisenhofer et al., 2004). DOPAC levels in the extracellular 
space range from 160-400 fmol/l while those of dopamine are in the range of 2 
fmol/l. Small changes in the intraneuronal pool of dopamine, which result in increased 
extracellular levels of the transmitter, may therefore not be reflected in the extracellular 
level of DOPAC. Thus, extracellular levels of DOPAC may not actually reflect the 
altered dynamics of deuterium dopamine metabolism. In addition, DOPAC is not a 
direct product of MAO metabolism (see Figure 5). In contrast, the direct product, 
DOPAL, may provide a better indication of MAO activity. DOPAL is an unstable 
intermediate which makes it difficult to quantify. However, DOPAL has successfully 
been measured in two microdialysis studies (Colzi et al., 1996, Fornai et al., 2000). 
Fornai (2000) showed that DOPAL levels are dramatically increased following L-
DOPA administration. To further gain insight into the details of dopamine metabolism 
following α,β,β-D3-L-DOPA administration it would therefore be of considerable 
interest to compare the effects of L-DOPA and α,β,β-D3-L-DOPA on DOPAL 
formation. 
 
The finding that DOPAC levels were readily elevated by L-DOPA also in the lesioned 
striatum (Figure 11 B) and that this increase was insensitive to MAO-B inhibition, 
suggests that DOPAC mainly originates from MAO-A activity, although the site of 
DOPAC formation remains unknown.The significant increase in dopamine levels 
following MAO-B inhibition and lack of reduction in L-DOPA-induced DOPAC levels 
could however readily be explained by the small contribution that this fraction of 
extracellular dopamine would have on the total formation of DOPAC in the lesioned 
striatum.  
 
4.2.3.2 3-MT 
3-MT has been proposed to provide a better index of changes in extracellular dopamine 
as compared to DOPAC (Brown et al., 1991, Kuczenski and Segal, 1992) as it is 
exclusively formed from dopamine metabolism by COMT in the extracellular space 
Results and Discussion 
 
45 
 
(Kastner et al., 1994, Karhunen et al., 1995). 3-MT levels were monitored in the 
lesioned striatum (see Figure 11 C) and were found to increase following α,β,β-D3-L-
DOPA and selegiline/L-DOPA treatment as compared to administration of L-DOPA 
alone. This may be the direct consequence of the increased elevation of extracellular 
levels of dopamine levels seen following these two treatments. Alternatively, since 
deamination of 3-MT to HVA is catalyzed by MAO, the increased levels of 3-MT may 
possibly reflect a decreased rate of this reaction (see Figure 3). Interestingly, 3-MT has 
been shown to act as an agonist on the trace amine-associated receptor 1 as well as 
dopamine receptors and intracerebral infusion of 3-MT has been shown to stimulate 
locomotor activity (Nakazato and Akiyama, 2002, Sotnikova et al., 2010). The possible 
role of 3-MT in the mediation of behavioral effects produced by L-DOPA remains to 
be clarified, but may have contributed to motor activationin the present study, as all 
treatment groups with increased 3-MT levels, as compared to L-DOPA, also displayed 
increased motor activation (see section 4.3.1). 
 
In conclusion, our data show that α,β,β-D3-L-DOPA provides a means to alter the 
dynamics of dopamine handling by MAO as well as DβH without direct enzyme 
inhibition, i.e. dopamine and noradrenaline output may be altered by both primary and 
secondary isotope effects on dopamine metabolism in vivo. These deuterium isotope 
effects, that are produced following administration of α,β,β-D3-L-DOPA, may also 
translate into an altered behavioral profile as compared to that of L-DOPA, which 
subsequently will be discussed. 
 
4.3 BEHAVIORAL EFFECTS OF α,β,β-D3-L-DOPA IN ANIMAL MODELS 
OF PARKINSON´S DISEASE (PAPER I, II AND III) 
As previously concluded, the increased half-life of dopamine produced from α,β,β-D3-
L-DOPA may provide substantial benefits in the treatment of PD. Therefore, the next 
series of experiments were performed in well established animal models of PD and 
were designed to estimate the acute behavioral potency of α,β,β-D3-L-DOPA as well as 
its effects on parkinsonian-like motor dysfunction and dyskinesia during chronic 
treatment. 
 
4.3.1 Acute behavioral potency of α,β,β-D3-L-DOPA 
In the reserpine model of PD, locomotor activity was automatically quantified 
following administration of L-DOPA, α,β,β-D3-L-DOPA and β,β-D2-L-DOPA (200 
mg/kg). While both L-DOPA and α,β,β-D3-L-DOPA reversed the reserpine-induced 
akinesia, the effect elicited by α,β,β-D3-L-DOPA was of significantly larger magnitude 
as compared to that of L-DOPA (see Figure 12).The ββ-D2-L-DOPA isoform, which 
had been shown to display an increased turnover of dopamine in dialysis experiments 
(see Figure 8), was unable to stimulate locomotor activity. The reversal of reserpine-
induced akinesia by L-DOPA is known to reflect a significant dopamine formation and 
postsynaptic receptor activation. Taken togheter, our data suggest that the increased 
locomotor activity produced by α,β,β-D3-L-DOPA predominantly or even exclusively 
depends on an increased dopamine output. 
Torun Malmlöf 
 
46 
 
 
Figure 12 Effects of vehicle (in 
non-reserpinized rats), carbidopa 
(10 mg/kg i.p) + vehicle, L-
DOPA (200 mg/kg i.p), β,β-D2-
L-DOPA (200 mg/kg i.p) or 
α,β,β- D3-L-DOPA(200 mg/kg 
i.p) on locomotor activity in 
reserpinized rats. Rats were 
placed in the locomotor activity 
boxes 10 minutes after the second 
injection. Data are expressed as 
mean ± S.E.M. ***=p<0.001, 
*p=<0.05 α,β,β-D3-L-DOPA 
versus L-DOPA.  
 
α,β,β-D3-L-DOPA and L-DOPA were subsequently compared in the 6-OHDA-
lesioned rat (Paper II and III). The unilateral 6-OHDA lesion induces an asymmetry in 
the body which, among other motor abnormalities, can be observed as a rotational 
behavior (see section 1.4.1.1). We used L-DOPA-induced rotation to establish a dose-
response curve of the acute effect of L-DOPA and α,β,β-D3-L-DOPA (D3-L-DOPA), 
as the intensity of rotation may relect quantative aspects of dopaminergic transmission 
(Ungerstedt, 1976, Schwarting and Huston, 1996). In Paper II, the total number of 
contralateral rotations performed up to 3 hours following administration of different 
doses of L-DOPA and D3-L-DOPA (3-8 mg/kg) was measured. The dose-response 
curve for D3-L-DOPA was shifted to the left, which indicates an increased potency 
(see Figure 13). The equipotent dose of α,β,β-D3-L-DOPA to L-DOPA was graphically 
determined at 50% of the rotational response (EC50) induced by the highest drug doses 
administered and found to correspond to ≈60% of a given L-DOPA dose.  
 
 
Figure 13. Dose-effect curve for 
the acute behavioral response to 
α,β,β-D3-L-DOPA and L-DOPA 
as measured by contralateral 
rotation (0-180 minutes post-
injection). L-DOPA (3.2, 6.4 and 
8 mg/kg) and D3-L-DOPA (3.2, 
4.8 and 6.4 mg/kg) were 
administered s.c (n=5-6/ dose). 
The line represents 50% of the 
effect mediated by the highest 
doses, the equipotent dose of 
α,β,β-D3-L-DOPA to L-DOPA 
was graphically determined at 
this point. Data are presented as 
mean ±SEM.  
 
 
In Paper III, the effect of the same dose (8 mg/kg) of D3-L-DOPA and L-DOPA were 
compared, alone as well as in combination with the clinically used MAO-B inhibitor 
selegiline (1 mg/kg). All treatments were first evaluated for acute behavioral effects and 
subsequently, following a wash-out period, neurochemical effects were studied in the 
lesioned striatum. The behavioral experiments were designed to simultaneously 
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monitor locomotor activity, L-DOPA-induced rotation and rearing activity. There was a 
trend towards increased locomotor activity in D3-L-DOPA -treated animals as well as 
in selegiline pretreated animals receiving L-DOPA or D3-L-DOPA, as compared to 
animals receiving L-DOPA alone. There were, however, no statistically significant 
differences between the groups (see Figure 14 A). A majority of the animals responded 
with ipsilateral rotation following L-DOPA and D3-L-DOPA treatment. Total 
rotational activity, independent of direction, was summarized to quantify behavioral 
activation in this study. D3-L-DOPA produced an increased rotational activity as 
compared to L-DOPA again confirming D3-L-DOPA’s increased potency (see Figure 
14 B). Moreover, selegiline pre-treatment was found to potentiate the effect of L-
DOPA, which is in line with its clinical effect in L-DOPA-treated PD patients (see 
section 1.3.3.2). Interestingly, the behavioral effect produced by D3-L-DOPA and 
selegiline/L-DOPA was of similar magnitude, which indirectly suggests that D3-L-
DOPA may provide equal clinical benefit as the combination of selegiline and L-
DOPA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Behavioral effects of L-DOPA 
and D3-L-DOPA alone and in combination 
with selegiline. Selegline 1 mg/kg or 
vehicle was injected one hour preceding the 
administration of L-DOPA or D3-L-DOPA 
(8 mg/kg s.c.). Data are presented as mean 
± SEM. A. Locomotor activity. Baseline 
(total activity performed 15 minutes 
preceding L-DOPA or D3-L-DOPA 
administration) is compared to treated (total 
activity performed for 120 minutes post-
injection). *p<0.05 and **p<0.01 compared 
to baseline. B. L-DOPA-induced rotation.  
Arrows indicate time of injection. *p<0.05 D3-L-DOPA versus L-DOPA; +p<0.05, ++p<0.01 
Selegiline/L-DOPA versus L-DOPA;¤p<0.05 D3-L-DOPA versus Selegiline/D3-L-DOPA. C. Rearing 
activity. The number of rearings performed using the left paw for support is presented as percent of the 
total number of rearings performed during baseline (15 minutes), vehicle/selegiline treatment (60 
minutes) and L-DOPA or D3-L-DOPA treatment (135 minutes). The line at 50% represents an equal use 
of both paws. **p<0.01 compared to baseline, ***p<0.001 compared to baseline and +p<0.05 compared 
to L-DOPA.  
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Limb use asymmetry was evaluated by scoring left and right paw supporting wall 
contacts during rearing activity. Unilateral lesions produce an asymmetric use of the 
forelimbs and an equal use of both limbs indicates that the asymmetry has been 
restored. All treatments were shown to significantly increase the use of the left 
parkinsonian limb for support during rearing activity (Figure 14 C). This finding 
indicates that, although the ipsilateral rotational response might be interpreted as a 
predominant activation of the intact striatum, dopaminergic transmission in the lesioned 
side was of sufficient magnitude to restore the lesion-induced asymmetry.  
 
In summary, D3-L-DOPA was shown to display an increased behavioral potency as 
compared to L-DOPA, evidenced by an increased locomotor activity in reserpinized 
animals and increased rotation activity in the 6-OHDA-lesioned animal. Although the 
study designs do not permit a direct correlation, the present behavioral data support the 
neurochemical observations of both primary and secondary isotope effects on 
dopamine metabolism following administration of D3-L-DOPA.  
 
4.3.2 Effects of D3-L-DOPA during chronic treatment (Paper II) 
The increased behavioral potency of D3-L-DOPA observed in parkinsonian animals 
indicates that the dose of the drug may be significantly reduced without a loss of the 
symptomatic effect, a property which may decrease the risk for motor complications. In 
order to test this hypothesis, a chronic treatment study was performed in 6-OHDA-
lesioned animals receiving daily injections of D3-L-DOPA and L-DOPA for three 
weeks. Four treatment groups were included; L-DOPA (8 mg/kg), D3-L-DOPA (8 
mg/kg), vehicle and an additional group treated with the equipotent dose of D3-L-
DOPA i.e. ≈60% of the L-DOPA dose (5 mg/kg), as determined from the acute dose-
response curve (see Figure 13).The anti-akinetic effects of the different treatments were 
evaluated using the cylinder and rotarod tests and the liability to induce dyskinesias was 
evaluated by the AIMs test. 
 
4.3.2.1 Effects of D3-L-DOPA and L-DOPA on parkinsonian-like motor dysfunction 
In the cylinder test the animal explores the cylinder by standing on the hindlimbs, 
supporting itself with the forelimbs against the cylinder wall. The rats were tested for 
baseline performance before the start of chronic treatment and the lesion was shown to 
reduce the use of the left limb to 25 % of all supporting contacts (see Figure 15 A). 
Treatment with L-DOPA did not improve performance relative to baseline values in the 
same animals, but there was a significant difference between the L-DOPA-treated and 
vehicle-treated animals confirming the anti-parkinsonian effect of L-DOPA previously 
observed in this test (Lundblad et al., 2002, Stefanova et al., 2004). Both the equipotent 
and equivalent dose of D3-L-DOPA produced a more pronounced anti-parkinsonian 
effect as compared to L-DOPA. This finding clearly supports the notion of an increased 
potency of the anti-parkinsonian effect produced by D3-L-DOPA. The rotarod test was 
intended to test the duration of the anti-akinetic response of L-DOPA and D3-L-DOPA 
as motor performance is measured at two different time-points, 20 and 140 min after 
drug administration. However, performance in the rotarod test was negatively 
compromised by dyskinesias during the course of the chronic treatment, an effect that 
was most pronounced in the groups treated with higher doses of the L-DOPA 
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compounds. Animals treated with the lower equipotent dose of D3-L-DOPA, remained 
on the rotarod for a longer time than vehicle-treated animals, indicating an anti-
parkinsonian effect of the drug in this test. Moreover, animals treated with the 
equivalent dose D3-L-DOPA showed improved performance at 140 minutes post 
injection. Although non-significant, these trends point in favor of the D3-L-DOPA-
treated groups (see Figure 15B).  
 
Figure 15. Anti-parkinsonian effects of D3-L-DOPA (5 and 8 mg/kg) and L-DOPA (8 mg/kg) during 
chronic treatment. A. The cylinder test. The rats were tested for baseline performance before the start of 
chronic-treatment (untreated) and during chronic treatment (treated). Within comparisons (untreated vs. 
treated), *=p<0.05; **=p<0.01; ***=p<0.001. Comparison between the groups (treated vs. treated), 
+=p<0.05; ++=p<0.01; +++=p<0.001 vs. vehicle; ¤=p<0.05 vs. D3-L-DOPA 8 mg/kg. B. The rotarod 
test. Animals were evaluated on the rotarod after a two-day drug free interval. Each trial consists of 90 s 
at accelerating speed; performance is presented as seconds on the rotarod and compared to vehicle-treated 
animals. The rats were tested 20 and 140 minutes post-injection of L-DOPA and D3-L-DOPA. Data are 
presented as mean ±SEM.  
 
4.3.2.2 Effects of D3-L-DOPA and L-DOPA on dyskiniesia 
Animals were scored for AIMs twice weekly during the course of the three-week 
treatment regimen. Treatment with the higher doses of L-DOPA and D3-L-DOPA 
produced a pronounced expression of AIMs from the first scoring session and 
throughout all the remaining sessions during the three-week experiment. Dyskinesia did 
not differ between animals treated with the equivalent doses of D3-L-DOPA and L-
DOPA (see Figure 16). In contrast, animals treated with the equipotent dose of D3-L-
DOPA expressed lower AIMs scores in all test sessions and, in addition, lower 
cumulative AIMs scores for the entire treatment period. Dyskinesia scores in animals 
treated with the high doses appeared to approach a ceiling effect, since a dose of L-
DOPA more than two times higher, previously was shown to result in comparable 
AIMs scores (Lindgren et al., 2007). Nevertheless, animals treated chronically with L-
DOPA expressed significantly higher AIMs in the last session as compared to the first; 
whereas no such effect was observed in either group treated with D3-L-DOPA (see 
Figure 16). Taken together, these findings indicate that the development of dyskinesia 
may have been slightly reduced during D3-L-DOPA treatment.  
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Figure 16. Effects of D3-L-DOPA and L-DOPA on development/expression AIMs. Data are presented 
as the cumulative AIMs score. Scoring was performed twice weekly for three weeks, resulting in a total 
of 6 sessions. Animals were scored every 20 minutes for 180 minutes after drug administration (9 
observations / animal / session). The maximal score for each of the three subtypes of AIMs was 4. A. 
Median cumulative AIMs score for each session. Maximal theoretical score for each session was 108 
(4*3*9). *= p<0.05 D3-L-DOPA 5mg/kg vs. L-DOPA 8 mg/kg; += p<0.05 D3-L-DOPA 5 mg/kg vs. 
D3-L-DOPA 8 mg/kg. B. Median cumulative AIMs score for the entire treatment period. Maximal 
theoretical score was 648 (4*3*9*6). *= p<0.05 D3-L-DOPA 5 vs. L-DOPA 8 mg/kg.  
 
A highly significant conclusion of this study is that deuterium substitutions in the L-
DOPA molecule allows for a significant dose reduction without loss of anti-
parkinsonian efficacy and a reduced incidence of dyskiniesia. As previously discussed, 
the risk for motor complications is positively correlated with L-DOPA dosage in PD 
patients (Schrag and Quinn, 2000, Sharma et al., 2006, Sharma et al., 2008). Similarly, 
the clinical benefit from L-DOPA treatment, as measured by the unified Parkinson´s 
disease rating scale, has previously been shown to increase dose-dependently (Fahn et 
al., 2004). Moreover, the therapeutic effect and side effects of a single dose of L-DOPA 
are not easily dissociated in dyskinetic patiens; therefore a reduction of the L-DOPA 
dose to control dyskinesia may compromise the therapeutic benefit. Our preclinical 
studies propose that D3-L-DOPA has a wider therapeutic window than L-DOPA. In the 
clinical setting D3-L-DOPA would thus allow for adequate control of the parkinsonian 
symptoms at an overall lower dosage which should be associated with lower risk for 
motor complications.  
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5 SUMMARY AND CONCLUDING REMARKS 
L-DOPA remains as the gold standard symptomatic treatment for PD, but long-term 
treatment with L-DOPA is complicated by the gradual emergence of motor 
complications. Risk factors for motor complications include disease severity, dosage of 
L-DOPA and duration of treatment (Schrag and Quinn, 2000, Fahn, 2005, Sharma et 
al., 2006, Sharma et al., 2008). While the mechanism underlying the emergence of 
motor complications remains largely unknown, non-physiological, pulsatile stimulation 
of postsynaptic dopamine receptors resulting from L-DOPA therapy is a prevailing 
hypothesis (Chase, 1998, Olanow et al., 2006). In the present thesis we investigated the 
potential utility of deuterium substitutions in the L-DOPA molecule to improve 
treatment of PD. Deuterium-L-DOPA was expected to yield dopamine more resistant to 
enzymatic degradation as deuterium forms a stronger bond with carbon.  
 
Among the deuteriated isoforms evaluated, α,β,β-D3-L-DOPA(D3-L-DOPA) was 
shown to significantly prolong the elevated striatal dopamine output as compared to the 
corresponding effect of L-DOPA. However, while L-DOPA also increased striatal 
output of noradrenaline, D3-L-DOPA left the striatal output of noradrenaline unaltered. 
In 6-OHDA-lesioned animals D3-L-DOPA was shown to produce an increased 
dopamine output as compared to L-DOPA administration. While the MAO-B inhibitor 
selegiline potentiated the effect of L-DOPA on striatal dopamine output, it did not 
potentiate D3-L-DOPA´s effect which closely resembled that of the selegiline/L-DOPA 
combination. An acute challenge with D3-L-DOPA was subsequently shown to 
produce a substantially larger motor activation than L-DOPA, both in the reserpine and 
the 6-OHDA-lesioned animal models of PD. In addition, the behavioral effect produced 
by D3-L-DOPA was found to be of similar magnitude as the combination of selegiline 
and L-DOPA. Chronic treatment with a significantly lower dose of D3-L-DOPA, i.e. 
60% of the administered L-DOPA dose, was found to produce similar anti-akinetic 
effect while the expression of dyskinetic movements was markedly reduced. In 
comparison with an equivalent dose of L-DOPA, D3-L-DOPA produced a larger anti-
akinetic effect but yet a similar expression of dyskinesia. Moreover, both doses of D3-
L-DOPA were associated with a seemingly reduced development of dyskinesia.  
 
Taken together, our data demonstrate an increased potency of D3-L-DOPA in 
comparison with L-DOPA and a widening of the therapeutic window. The 
neurochemical effect of D3-L-DOPA was studied under two conditions, i.e. in rats with 
an intact dopaminergic system or in rats with near complete dopamine denervation. The 
PD patient presents with motor symptoms when striatal tissue levels of dopamine have 
decreased by approximately 80% (Bernheimer et al., 1973), and the degenerative 
process slowly progresses over the years (Agid, 1991). The 6-OHDA rodent model 
studied herein, which is associated with ≈95% striatal dopamine denervation, might 
therefore be regarded as a model of late stage PD. The striatal output of dopamine 
following administration of D3-L-DOPA in the intact animals remained elevated for a 
longer period of time than the corresponding effect of L-DOPA, whereas this temporal 
difference was less pronounced in the lesioned striatum. Thus, the temporal difference 
in extracellular dopamine levels formed from L-DOPA and D3-L-DOPA is largely 
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related to D3-L-DOPA’s effect on the dynamics of dopamine release and clearance in 
the presence of dopaminergic terminals. It is therefore possible that D3-L-DOPA might 
produce an even more prolonged increase in striatal dopamine output in PD patients 
with less severe neurodegeneration, i.e. in early stage PD patients. Therefore, it is of 
considerable interest that the increased half-life of dopamine formed from D3-L-DOPA 
may protect against a subsequent development of dyskinesia in two ways. First, 
reduced fluctuations of dopamine levels should prevent pulsatile stimulation of 
dopamine receptors. Second, a prolonged half-life would allow an increased dosing 
interval, which in effect means a reduction of the total L-DOPA load. Indeed, at 60% of 
the corresponding L-DOPA dose, D3-L-DOPA produced equal anti-parkinsonian effect 
and dyskinesia was markedly reduced. In the late stage PD patient, adequate 
symptomatic treatment with D3-L-DOPA may therefore be associated with lower risk 
for motor complications.  
 
Primary and secondary isotope effects in the metabolism of dopamine formed from D3-
L-DOPA may have several mechanistic consequences depending on the level of 
integrity of the dopaminergic system, and the potential benefits with D3-L-DOPA can 
be derived from two convergent, but inter-dependent, mechanisms; an increased half-
life of dopamine formed from each dose of D3-L-DOPA and an increased potency. 
While the increased duration to a large extent may depend on the degree of integrity of 
presynaptic dopaminergic terminals, the increased potency is probably related to a 
combination of both pre- and postsynaptic mechanisms involving MAO-metabolism. 
Consequently, it may well be that in early stage PD patients, with less severe 
neurodegeneration, the dose of D3-L-DOPA, which would be required to a produce 
sufficient symptomatic effect, may be even lower than the 60% observed in our model 
of late stage PD.  
 
Although, MAO-A expression has been reported to be higher in rats than in humans 
(Fowler et al., 1987, Westlund et al., 1988, Saura et al., 1992), our data clearly 
demonstrate a role for postsynaptic MAO-B metabolism of dopamine formed from L-
DOPA in the lesioned rat. In man, postsynaptic MAO-B dependent dopamine 
metabolism is reported to be of even greater magnitude (Stenström et al., 1987), which 
largely may explain the clinical efficacy of MAO-B inhibitors in PD patients (Oreland 
et al., 1983). Our data showing that D3-L-DOPA increased extracellular levels of 
striatal dopamine to a similar extent as the combination of selegiline and L-DOPA and 
that selegiline was unable to potentiate the effects of D3-L-DOPA, indicate that the 
increased dopamine output in all three treatment groups may be attributed to decreased 
postsynaptic MAO-B dependent dopamine metabolism. Given the relatively less 
significant MAO-B dependent postsynaptic metabolism of dopamine in rats as 
compared to humans, treatment with D3-L-DOPA may be expected to be more 
efficient in PD patients than indicated by our experiments in lesioned rats. In addition, 
D3-L-DOPA offers the potential advantage over MAO-B-inhibitors to reduce 
presynaptic MAO-A metabolism, since MAO-A is the exclusive MAO isoform 
expressed in dopaminergic neurons across species. This effect may in turn augment 
synaptic levels of dopamine released from remaining terminals.  
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The reduced output of noradrenaline from D3-L-DOPA observed herein, may be 
attributed to decreased DβH activity towards the β-carbon (Miller and Klinman, 1983). 
Previous studies have suggested that a concomitant degeneration of central 
noradrenergic neurons may contribute to both the pathophysiology and 
symptomatology of PD, although severe degeneration of e.g. LC neurons has also been 
observed in Alzheimer´s disease which lacks the neurological core symptoms of PD 
(Hornykiewicz and Kish, 1987, Zarow et al., 2003, Fornai et al., 2007, Delaville et al., 
2011, McMillan et al., 2011). Interestingly, supplementation of noradrenaline with the 
synthetic precursor L-threo-3, 4-dihydroxyphenylserine (L-DOPS) has been reported to 
improve certain motor aspects in L-DOPA-treated PD patients (Ogawa et al., 1985, 
Tohgi et al., 1990). These data may thus suggest that augmentation of noradrenergic 
transmission might be useful in PD. It should be noted, however, that no consensus 
exists as regards the putative role of noradrenaline formed from L-DOPA for its 
therapeutic effect as well as its side effects in PD patients. Our data in intact animals 
clearly show that noradrenaline can be formed in the striatum following L-DOPA 
administration. However, the 6-OHDA used to lesion the dopaminergic system in our 
experiments also lesions noradrenergic neurons (Fulceri et al., 2007, Barnum et al., 
2012). Accordingly, L-DOPA did not increase noradrenaline output in lesioned animals 
and thus it seems highly unlikely that the behavioral differences observed between rats 
treated with L-DOPA and D3-L-DOPA, i.e. with regard to the anti-parkinsonian effect 
and occurrence dyskinesia, are indeed related to noradrenaline. The well-established, 
anti-dyskinetic effect of α2 antagonists in animal models may theoretically be related to 
blockade of either pre- or postsynaptic α2 receptors. As blockade of presynaptic 
autoreceptors will increase striatal noradrenaline release (Gobert et al., 2004) the 
antidyskinetic effect might be related to enhanced noradrenergic neurotransmission, but 
the effect may alternatively be due to blockade of postsynaptic α2 receptors. 
Significantly, a recent experimental study performed in 6-OHDA-lesioned rats showed 
that infusion of noradrenaline into the striatum triggered the onset of dyskinesia in L-
DOPA-treated animals (Buck and Ferger, 2009). This finding indicates that a putative 
formation of noradrenaline from L-DOPA in the striatum might, if anything, contribute 
to enhance the expression of dyskinesia by activation of postsynaptic receptors. 
Consequently, the reduced formation of noradrenaline from D3-L-DOPA may well 
even serve to dampen the expression of LID. 
 
The most important conclusion from the present set of preclinical experiments is that 
deuterium substitutions in the L-DOPA molecule allows for a significant dose 
reduction without loss of anti-parkinsonian efficacy and a reduced incidence of 
dyskinesia. In short, D3-L-DOPA appears clearly more potent and exhibits a wider 
therapeutic window than L-DOPA, which implies that the anti-parkinsonian effect and 
the risk for motor complications may be dissociated. In principle, our findings thus 
argue against the current assumption that drugs that increase dopaminergic transmission 
inevitably also increase the expression of dyskinesia (Encarnacion and Hauser, 2008, 
Nutt, 2008). The present results suggest that in the clinical setting treatment with D3-L-
DOPA may offer several potential advantages over available pharmacotherapies used 
in PD, including conventional L-DOPA. A prolonged anti-parkinsonian effect of each 
dose may contribute to delay both the gradual development and expression of motor 
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fluctuations and dyskinesias. The higher potency of D3-L-DOPA should allow for 
adequate control of parkinsonian symptoms at an overall lower dosage and would 
thereby contribute to an additional reduction of the risk for motor complications. 
Finally, the lower dose of D3-L-DOPA needed for therapeutic effect may also reduce 
the expression of already established dyskinesia. In all simplicity, the similar effect 
produced by D3-L-DOPA and the combination of selegiline and L-DOPA suggest a 
potential clinical advantage of monotherapy with D3-L-DOPA in the treatment of PD. 
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